

AUTHOR INDEX FOR VOLUME 43

A

- Abe, H., *see* Ohmori, S., 183
 Adham, N., Ellerbrock, B., Hartig, P., Weinshank, R. L., and Branchek, T. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine_{1B} receptor expression system, 427
 Ahmad, S., and Glazer, R. I. Expression of the antisense cDNA for protein kinase C α attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells, 858
 Akiyoshi, J., Hough, C., and Chuang, D.-M. Paradoxical increase of 5-hydroxytryptamine₂ receptors and 5-hydroxytryptamine₂ receptor mRNA in cerebellar granule cells after persistent 5-hydroxytryptamine₂ receptor stimulation, 349
 Aksoy, I. A., *see* Honchel, R., 878
 Allegra, C. J., *see* Chu, E., 527
 Allison, A. C., *see* Amano, Y., 176
 Amano, Y., Lee, S. W., and Allison, A. C. Inhibition by glucocorticoids of the formation of interleukin-1 α , interleukin-1 β , and interleukin-6: Mediation by decreased mRNA stability, 176
 Amlaiky, N., *see* Matthes, H., 313
 Ammer, H., and Schulz, R. Coupling of prostaglandin E₁ receptors to the stimulatory GTP-binding protein G_s is enhanced in neuroblastoma $\times$ glioma (NG108-15) hybrid cells chronically exposed to an opioid, 556
 Anders, E.-M., *see* Fuhr, U., 191
 Andres, H., *see* Quast, U., 474
 Anné, J., *see* Debyser, Z., 521
 Aramori, I., Nirei, H., Shoubo, M., Sogabe, K., Nakamura, K., Kojo, H., Notsu, Y., Ono, T., and Nakanishi, S. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells, 127
 Arellano, L., *see* Santostefano, M., 200
 Armstrong, S. G., and Renton, K. W. Mechanism of hepatic cytochrome P450 modulation during *Listeria monocytogenes* infection in mice, 542
 Arndts, D., *see* Kratwurst, D., 655
 Arriza, J. L., *see* Kurose, H., 444
 Artymyshyn, R. P., *see* Boundy, V. A., 666
 Asaoka, K., *see* Ohmori, S., 183
 Ashburn, S. P., Han, X., and Liehr, J. G. Microsomal hydroxylation of 2- and 4-fluoroestradiol to catechol metabolites and their conversion to methyl ethers: Catechol estrogens as possible mediators of hormonal carcinogenesis, 534
 Audia, J. E., *see* Wainscott, D. B., 419
 Ault-Riché, D. B., Lee, Y., Yuan, C.-S., Hasobe, M., Wolfe, M. S., Borcharding, D. R., and Borchardt, R. T. Effects of 4'-modified analogs of aristeromycin on the metabolism of S-adenosyl-L-homocysteine in murine L929 cells, 989
 Austin, E. A., and Huber, B. E. A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of *Escherichia coli* cytosine deaminase, 380
 Azoulay, D., *see* Lemoine, A., 827

B

- Baekelandt, V., *see* Debyser, Z., 521
 Baez, M., *see* Wainscott, D. B., 419
 Balzarini, J., Velazquez, S., San-Felix, A., Karlsson, A., Perez-Perez, M.-J., Camarasa, M.-J., and De Clercq, E. Human immunodeficiency virus type 1-specific [2',5'-bis-(*tert*-butyldimethylsilyl)- β -D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues, 109
 Bangert, M., *see* Niroomand, F., 90
 Barber, R., *see* Stickle, D. F., 397
 Barnes, P. J., *see* Ring, P. C., 302
 Baudry, M., *see* Hall, R. A., 459
 Baumlin, Y., *see* Quast, U., 474
 Bazmi, H. Z., *see* Mellors, J. W., 11
 Beaune, P., *see* Botsch, S., 120
 Beaune, P., *see* Lemoine, A., 827
 Bebenek, K., Thomas, D. C., Roberts, J. D., Eckstein, F., and Kunkel, T. A. Effects of 3'-azido-3'-deoxythymidine metabolites on Simian virus 40 origin-dependent replication and heteroduplex repair in HeLa cell extracts, 57
 Bell, G. I., *see* Raynor, K., 838
 Belloc, C., *see* Lemoine, A., 827
 Berger, S. H., *see* Davis, S. T., 702
 Bhat, R., *see* Chanda, P. K., 516
 Bhikhabhai, R., *see* Debyser, Z., 521
 Biaggioni, I., *see* Feoktistov, I., 909
 Birnbaumer, L., *see* Gudermann, T., 412
 Birnbaumer, M., *see* Gudermann, T., 412
 Bocherding, D. R., *see* Ault-Riché, D. B., 989
 Bockaert, J., *see* Dumuis, A., 976
 Boer, R., *see* Lakitsch, M., 293
 Bolaños, J. P., and Medina, J. M. Evidence of stimulation of the γ -aminobutyric acid shunt by valproate and *E*- Δ^2 -valproate in neonatal rat brain, 487
 Bonin, H., *see* Nantel, F., 548
 Borchardt, R. T., *see* Ault-Riché, D. B., 989
 Boschert, U., *see* Matthes, H., 313
 Bossé, R., *see* Servant, G., 677
 Botsch, S., Gautier, J.-C., Beaune, P., Eichelbaum, M., and Kroemer, H. K. Identification and characterization of the cytochrome P450 enzymes involved in *N*-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites, 120
 Boulay, G., *see* Servant, G., 677
 Boundy, V. A., Luedtke, R. R., Artymyshyn, R. P., Filtz, T. M., and Molinoff, P. B. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides, 666
 Bouvier, M., *see* Nantel, F., 548
 Bowlby, M. R. Pregnenolone sulfate potentiation of *N*-methyl-D-aspartate receptor channels in hippocampal neurons, 813
 Bradford, B. U., Forman, D. T., and Thurman, R. G. 4-Methylpyrazole inhibits fatty acyl coenzyme A synthetase and diminishes catalase-dependent alcohol metabolism: Has the contribution of alcohol dehydrogenase to alcohol metabolism been previously overestimated? 115
 Branchek, T., *see* Adham, N., 427
 Bray, K. M., *see* Quast, U., 474
 Breliere, J. C., *see* Rinaldi-Carmona, M., 84
 Brooker, G., *see* DeBarnardi, M. A., 451
 Brown, D. R., *see* Hildebrand, K. R., 23
 Brüne, B., *see* Wu, X.-B., 564
 Buckley, N. J., *see* Steel, M. C., 694
 Burchell, B., *see* Ebner, T., 649
 Burkitt, M. J., Kadiiska, M. B., Hanna, P. M., Jordan, S. J., and Mason, R. P. Electron spin resonance spin-trapping investigation

into the effects of paraquat and desferrioxamine on hydroxyl radical generation during acute iron poisoning, 257

Burrows, G. G., *see* Moebius, F. F., 139

Burt, H. M., Jackson, J. K., Dryden, P., and Salari, H. Crystal-induced protein tyrosine phosphorylation in neutrophils and the effect of a tyrosine kinase inhibitor on neutrophil responses, 30

Butler, A. M., and Murray, M. Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion, 902

C

Cai, J. J., *see* Chatterjee, T. K., 167

Camarasa, M.-J., *see* Balzarini, J., 109

Capranico, G., *see* De Isabella, P., 715

Carbone, R., *see* Jancis, E. M., 51

Carter, B. D., and Medzihradsky, F. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells, 465

Carter, D. B., *see* Pregoner, J. F., 801

Catterall, W. A., *see* Ragsdale, D., 949

Catterall, W. A., *see* Thomsen, W., 955

Chaki, S., and Inagami, T. New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: Activation of soluble guanylyl cyclase via nitric oxide synthesis, 603

Chanda, P. K., Minchin, M. C. W., Davis, A. R., Greenberg, L., Reilly, Y., McGregor, W. H., Bhat, R., Lubeck, M. D., Mizutani, S., and Hung, P. P. Identification of residues important for ligand binding to the human 5-hydroxytryptamine_{1A} serotonin receptor, 516

Chandra, A., *see* Karolak, L., 37

Chatterjee, T. K., Moy, J. A., Cai, J. J., Lee, H.-C., and Fisher, R. A. Solubilization and characterization of a guanine nucleotide-sensitive form of the calcitonin gene-related peptide receptor, 167

Chen, K., *see* Wu, H.-F., 888

Cheng, Y.-c., *see* Gao, W.-Y., 45

Cheng, Y.-c., *see* Mellors, J. W., 11

Cho-Chung, Y. S., *see* Rohlf, C., 372

Choudhary, M. S., Craig, S., and Roth, B. L. A single point mutation (Phe³⁴⁰→Leu³⁴⁰) of a conserved phenylalanine abolishes 4-[¹²⁵I]iodo-(2,5-dimethoxy)phenylisopropylamine and [³H]mesulergine but not [³H]ketanserin binding to 5-hydroxytryptamine₂ receptors, 755

Chu, D. T. W., *see* Fuhr, U., 191

Chu, E., Koeller, D. M., Johnston, P. G., Zinn, S., and Allegra, C. J. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon- γ , 527

Chuang, D.-M., *see* Akiyoshi, J., 349

Ciaccio, P. J., Stuart, J. E., and Tew, K. D. Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells, 845

Ciesla, W., *see* Yasuda, R. P., 149

Clement, B., Jung, F., and Pfunder, H. N-Hydroxylation of benzamidine to benzamidoxime by a reconstituted cytochrome P-450 oxidase system from rabbit liver: Involvement of cytochrome P-450 IIC3, 335

Cohen, M. L., *see* Wainscott, D. B., 419

Coleman, B. A., and Oswald, R. E. Identification of the benzomorphan opiate binding site on the catalytic subunit of acetylcholinesterase, 217

Comer, K. A., *see* Wilborn, T. W., 70

Congy, C., *see* Rinaldi-Carmona, M., 84

Conway, B. R., Withiam-Leitch, M., and Rubin, R. P. Regulation of phosphatidylinositol 4-kinase activity in rat pancreatic acini, 286

Costa, T., *see* Onaran, H. O., 245

Coy, D. H., *see* Mantey, S., 762

Coy, D. H., *see* Raynor, K., 838

Cragoe, E. J., Jr., *see* Dumuis, A., 976

Craig, S., *see* Choudhary, M. S., 755

D

Dannies, P. S., *see* Jancis, E. M., 51

Davis, A. R., *see* Chanda, P. K., 516

Davis, S. T., and Berger, S. H. Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2'-deoxyuridine, 702

DeBernardi, M. A., Munshi, R., and Brooker, G. Ca²⁺ inhibition of β -adrenergic receptor- and forskolin-stimulated cAMP accumulation in C6-2B rat glioma cells is independent of protein kinase C, 451

Debyser, Z., De Vreese, K., Knops-Gerrits, P. P., Baekelandt, V., Bhikhabhai, R., Strandberg, B., Pauwels, R., Anné, J., Desmyter, J., and De Clercq, E. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors, 521

De Clercq, E., *see* Balzarini, J., 109

De Clercq, E., *see* Debyser, Z., 521

De Isabella, P., Capranico, G., Palumbo, M., Sissi, C., Krapcho, A. P., and Zunino, F. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: Relationships to drug DNA binding and cellular effects, 715

DeJong, A. P., *see* Makriyannis, A., 78

De Léan, A., *see* Mimeault, M., 775

Demchyshyn, L. L., Srikant, C. B., Sunahara, R. K., Kent, G., Seeman, P., Van Tol, M., Panetta, R., Patel, Y. C., and Niznik, H. B. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20, 894

de Moraes, S. M. F., *see* Kaminsky, L. S., 234

Denison, M. S., *see* Santostefano, M., 200

De Riel, J. K., *see* Mauro, D. J., 854

Descamps-Latscha, B., *see* Taupin, V., 64

Desmyter, J., *see* Debyser, Z., 521

De Vreese, K., *see* Debyser, Z., 521

DiMeglio, C. M., *see* Makriyannis, A., 78

Dionne, V. E., *see* Gurantz, D., 807

Dissanayake, V. U. K., *see* Hunter, J. C., 595

Dooley, T. P., *see* Wilborn, T. W., 70

Dosogne, J., *see* Quast, U., 474

Dryden, P., *see* Burt, H. M., 30

Dubreuil, D., *see* Safrany, S. T., 499

Duescher, R. J., *see* Sausen, P. J., 388

Dumuis, A., Sebben, M., Fagni, L., Prézeau, L., Manzoni, O., Cragoe, E. J., Jr., and Bockaert, J. Stimulation by glutamate receptors of arachidonic acid release depends on the Na⁺/Ca²⁺ exchanger in neuronal cells, 976

Dunbar, D. A., *see* Fasco, M. J., 226

Dunbar, D. A., *see* Kaminsky, L. S., 234

Dutschman, G. E., *see* Mellors, J. W., 11

E

Ebner, T., Rimmel, R. P., and Burchell, B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol, 649

Eckstein, F., *see* Bebenek, K., 57

Egan, W., *see* Gao, W.-Y., 45

Eichelbaum, M., *see* Botsch, S., 120

Elfarr, A. A., *see* Sausen, P. J., 388

El-Khateeb, S., *see* Makriyannis, A., 78

Ellerbrock, B., *see* Adham, N., 427

Emorine, L. J., *see* Nantel, F., 548

Eriksson, A., *see* Malmberg, Å., 749

Escher, E., *see* Servant, G., 677

Eskildsen, L. A., *see* Sullivan, D. M., 207

F

- Fagni, L., *see* Dumuis, A., 976
 Falany, C. N., *see* Wilborn, T. W., 70
 Falletto, M. B., *see* Kaminsky, L. S., 234
 Fasco, M. J., Silkworth, J. B., Dunbar, D. A., and Kaminsky, L. S. Rat small intestinal cytochromes P450 probed by warfarin metabolism, 226
 Felder, R. A., *see* Horiuchi, A., 281
 Feoktistov, I., and Biaggioni, I. Characterization of adenosine receptors in human erythroleukemia cells and platelets: Evidence for heterogeneity of adenosine A₂ receptor subtypes, 909
 Ferry, R. C., Unsworth, C. D., and Molinoff, P. B. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine₂ receptors in P11 cells, 726
 Féthiere, J., *see* Mimeault, M., 775
 Filtz, T. M., *see* Boundy, V. A., 666
 Fisher, R. A., *see* Chatterjee, T. K., 167
 Fleming, W. W., *see* Hershman, K. M., 833
 Flockerzi, D., *see* Lakitsch, M., 293
 Flores, L. R., *see* Yasuda, R. P., 149
 Follesa, P., and Mocchetti, I. Regulation of basic fibroblast growth factor and nerve growth factor mRNA by β -adrenergic receptor activation and adrenal steroids in rat central nervous system, 132
 Forman, D. T., *see* Bradford, B. U., 115
 Fournier, A., *see* Mimeault, M., 775
 Frucht, H., *see* Mantey, S., 762
 Fuhr, U., Strobl, G., Manaut, F., Anders, E.-M., Sörgel, F., Lopez-de-Brinas, E., Chu, D. T. W., Pernet, A. G., Mahr, G., Sanz, F., and Staib, A. H. Quinolone antibacterial agents: Relationship between structure and *in vitro* inhibition of the human cytochrome P450 isoform 1A2, 191

G

- Gallagher, T. K., *see* Wang, C.-D., 931
 Gao, W.-Y., Storm, C., Egan, W., and Cheng, Y.-c. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells, 45
 Gautier, J.-C., *see* Botsch, S., 120
 Gautier, J. C., *see* Lemoine, A., 827
 Gibson, G. G., *see* Perry, S. J., 660
 Giembycz, M. A., *see* Ring, P. C., 302
 Gilbert, T., *see* Smith, R. A., 741
 Glaum, S. R., and Miller, R. J. Zinc protoporphyrin-IX blocks the effects of metabotropic glutamate receptor activation in the rat nucleus tractus solitarius, 965
 Glazer, R. I., *see* Ahmad, S., 858
 Glazer, R. I., *see* Rohlf, C., 372
 Glossmann, H., *see* Lakitsch, M., 293
 Glossmann, H., *see* Moebius, F. F., 139
 Gogusev, J., *see* Taupin, V., 64
 Goldfarb, P. S., *see* Perry, S. J., 660
 Goldin, A. L., *see* Kontis, K. J., 635
 Goldstein, J. A., *see* Kaminsky, L. S., 234
 Gonzalez, C. J., *see* Mellors, J. W., 11
 Gonzalez, F. J., *see* Kapitulnik, J., 722
 Graesser, D., and Neubig, R. R. Compartmentation of receptors and guanine nucleotide-binding proteins in NG108-15 cells: Lack of cross-talk in agonist binding among the α_2 -adrenergic, muscarinic, and opiate receptors, 434
 Grailhe, R., *see* Matthes, H., 313
 Greenberg, C. S., *see* Karolak, L., 37
 Greenberg, L., *see* Chanda, P. K., 516
 Greenidge, P. A., Jenkins, T. C., and Neidle, S. DNA minor groove recognition properties of pentamidine and its analogs: A molecular modeling study, 982
 Groom, K. R., *see* Sullivan, D. M., 207
 Gudermann, T., Levy, F. O., Birnbaumer, M., Birnbaumer, L., and

- Kaumann, A. J. Human S31 serotonin receptor clone encodes a 5-hydroxytryptamine_{1E}-like serotonin receptor, 412
 Guengerich, F. P., *see* Lemoine, A., 827
 Guillemette, G., *see* Servant, G., 677
 Gurantz, D., Margiotta, J. F., Harootunian, A. T., and Dionne, V. E. Modulation by albumin of neuronal cholinergic sensitivity, 807
 Guzelian, P. S., *see* Kocarek, T. A., 328

H

- Hadingham, K. L., Wingrove, P., Le Bourdelles, B., Palmer, K. J., Ragan, C. I., and Whiting, P. J. Cloning of cDNA sequences encoding human α_2 and α_3 γ -aminobutyric acid_A receptor subunits and characterization of the benzodiazepine pharmacology of recombinant α_1 -, α_2 -, α_3 -, and α_5 -containing human γ -aminobutyric acid_A receptors, 970
 Hall, R. A., Massicotte, G., Kessler, M., Baudry, M., and Lynch, G. Thiocyanate equally increases affinity for two DL- α -amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor states, 459
 Hamblin, M. W., *see* Monsma, F. J., Jr., 320
 Hammer, R., *see* Kratwurst, D., 655
 Han, X., *see* Ashburn, S. P., 534
 Hanna, P. M., *see* Burkitt, M. J., 257
 Hannun, Y. A., *see* Karolak, L., 37
 Harootunian, A. T., *see* Gurantz, D., 807
 Harris, R. A., *see* Lin, L.-H., 941
 Harrison, N. L., Radke, H. K., Tamkun, M. M., and Lovinger, D. M. Modulation of gating of cloned rat and human K⁺ channels by micromolar Zn²⁺, 482
 Hartig, P., *see* Adham, N., 427
 Hasobe, M., *see* Ault-Riché, D. B., 989
 Hays, S. J., *see* Thomsen, W., 955
 Heinrikson, R. L., *see* Wilborn, T. W., 70
 Hen, R., *see* Matthes, H., 313
 Hering, S., Savchenko, A., Strübing, C., Lakitsch, M., and Striessnig, J. Extracellular localization of the benzothiazepine binding domain of L-type Ca²⁺ channels, 820
 Hershman, K. M., Taylor, D. A., and Fleming, W. W. Adaptive supersensitivity in the guinea pig vas deferens is associated with a reduction in the abundance of the α_2 subunit isoform of Na⁺/K⁺-ATPase, 833
 Hescheler, J., *see* Kratwurst, D., 655
 Hicks, J. L., *see* Thomsen, W., 955
 Hildebrand, K. R., Lin, G., Murtaugh, M. P., and Brown, D. R. Molecular characterization of α_2 -adrenergic receptors regulating intestinal electrolyte transport, 23
 Hill, D. R., *see* Hunter, J. C., 595
 Hipsher, C., *see* Pan, S.-S., 863
 Hiraoka, M., *see* Nishio, M., 96
 Hoeltje, H.-D., *see* Lakitsch, M., 293
 Hollenberg, M. D., Laniyonu, A. A., Saifeddine, M., and Moore, G. J. Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: Evidence for receptor subtypes, 921
 Honchel, R., Aksoy, I. A., Szumlanski, C., Wood, T. C., Otterness, D. M., Wieben, E. D., and Weinshilboum, R. M. Human thiopurine methyltransferase: Molecular cloning and expression of 8784 colon carcinoma cell cDNA, 878
 Horie, T., *see* Ohmori, S., 183
 Horiuchi, A., Takeyasu, K., Mouradian, M. M., Jose, P. A., and Felder, R. A. D_{1A} Dopamine receptor stimulation inhibits Na⁺/K⁺-ATPase activity through protein kinase A, 281
 Horne, P., *see* Williams, R. J., 158
 Horwell, D. C., *see* Hunter, J. C., 595
 Hough, C., *see* Akiyoshi, J., 349
 Houston, D. B., and Howlett, A. C. Solubilization of the cannabinoid

- receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins, 17
- Howlett, A. C., *see* Houston, D. B., 17
- Huber, B. E., *see* Austin, E. A., 380
- Hughes, J., *see* Hunter, J. C., 595
- Hung, P. P., *see* Chanda, P. K., 516
- Hunter, J. C., Suman-Chauhan, N., Meecham, K. G., Dissanayake, V. U. K., Hill, D. R., Pritchard, M. C., Kneen, C. O., Horwell, D. C., Hughes, J., and Woodruff, G. N. [³H]PD 140376: A novel and highly selective antagonist radioligand for the cholecystokinin_B/gastrin receptor in guinea pig cerebral cortex and gastric mucosa, 595

I

- Im, G.-j., *see* Mellors, J. W., 11
- Im, W. B., *see* Pregenzer, J. F., 801
- Inagami, T., *see* Chaki, S., 603
- Innis, R. B., *see* Wall, S. C., 264

J

- Jackson, D. M., *see* Malmberg, Å., 749
- Jackson, J. K., *see* Burt, H. M., 30
- Jancis, E. M., Carbone, R., Loechner, K. J., and Dannies, P. S. Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells, 51
- Jenkins, T. C., *see* Greenidge, P. A., 982
- Jensen, R. T., *see* Mantey, S., 762
- Johnston, P. G., *see* Chu, E., 527
- Jordan, S. J., *see* Burkitt, M. J., 257
- Jose, P. A., *see* Horiuchi, A., 281
- Jung, F., *see* Clement, B., 335

K

- Kadiiska, M. B., *see* Burkitt, M. J., 257
- Kaminsky, L. S., de Moraes, S. M. F., Faletto, M. B., Dunbar, D. A., and Goldstein, J. A. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe, 234
- Kaminsky, L. S., *see* Fasco, M. J., 226
- Kanakubo, Y., *see* Ohmori, S., 183
- Kandel, M., *see* Sinkins, W. G., 569
- Kandel, S. I., *see* Sinkins, W. G., 569
- Kaneda, T., Kitamura, Y., and Nomura, Y. Presence of m3 subtype muscarinic acetylcholine receptors and receptor-mediated increase in the cytoplasmic concentration of Ca²⁺ in Jurkat, a human leukemic helper T lymphocyte line, 356
- Kapitulnik, J., and Gonzalez, F. J. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat, 722
- Karlsson, A., *see* Balzarini, J., 109
- Karolak, L., Chandra, A., Khan, W., Marks, B., Petros, W. P., Peters, W. P., Greenberg, C. S., and Hannun, Y. A. High-dose chemotherapy-induced platelet defect: Inhibition of platelet signal transduction pathways, 37
- Kaufman, S., *see* Sakai, N., 6
- Kaumann, A. J., *see* Gudermann, T., 412
- Kelly, E., *see* Williams, R. J., 158
- Kemp, J. A., *see* Wafford, K. A., 240
- Kent, G., *see* Demchyshyn, L. L., 894
- Kessler, M., *see* Hall, R. A., 459
- Khan, W., *see* Karolak, L., 37
- Kiffel, L., *see* Lemoine, A., 827
- Kigoshi, S., *see* Nishio, M., 96
- King, L. J., *see* Perry, S. J., 660
- Kirkland, J. L., Murthy, L., and Stancel, G. M. Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus, 709
- Kitada, M., *see* Ohmori, S., 183

- Kitagawa, H., *see* Ohmori, S., 183
- Kitamura, Y., *see* Kaneda, T., 356
- Klecker, R. W., *see* Rohlf, C., 372
- Knaus, H.-G., *see* Lakitsch, M., 293
- Kneen, C. O., *see* Hunter, J. C., 595
- Knops-Gerrits, P. P., *see* Debyser, Z., 521
- Kocarek, T. A., Schuetz, E. G., and Guzelian, P. S. Expression of multiple forms of cytochrome P450 mRNAs in primary cultures of rat hepatocytes maintained on Matrigel, 328
- Koeller, D. M., *see* Chu, E., 527
- Kojo, H., *see* Aramori, I., 127
- Kontis, K. J., and Goldin, A. L. Site-directed mutagenesis of the putative pore region of the rat IIA sodium channel, 635
- Krapcho, A. P., *see* De Isabella, P., 715
- Kratwurst, D., Hescheler, J., Arndts, D., Lösel, W., Hammer, R., and Schultz, G. Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells, 655
- Kroeger, P. E., *see* Sullivan, D. M., 207
- Kroemer, H. K., *see* Botsch, S., 120
- Kunkel, T. A., *see* Bebenek, K., 57
- Kurose, H., Arriza, J. L., and Lefkowitz, R. J. Characterization of α₂-adrenergic receptor subtype-specific antibodies, 444
- Kursar, J. D., *see* Wainscott, D. B., 419

L

- Lakitsch, M., Knaus, H.-G., Topar, G., Romanin, C., Boer, R., Flockerzi, D., Striessnig, J., Schindler, H., Hoeltje, H.-D., Glossmann, H. Heterogeneity of L-type calcium channel α₁ subunits: Stereoselective discrimination of different populations by the novel 1,4-dihydropyridine B 874-67, 293
- Lakitsch, M., *see* Hering, S., 820
- Laniyonu, A. A., *see* Hollenberg, M. D., 921
- Latham, M. D., *see* Sullivan, D. M., 207
- Law, P. Y., and Loh, H. H. δ-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma × glioma NG108-15 hybrid cells, 684
- Le Bourdelles, B., *see* Handingham, K. L., 970
- Lee, H.-C., *see* Chatterjee, T. K., 167
- Lee, S. W., *see* Amano, Y., 176
- Lee, Y., *see* Ault-Riché, D. B., 989
- Lefkowitz, R. J., *see* Kurose, H., 444
- Le Fur, G., *see* Rinaldi-Carmona, M., 84
- Lemoine, A., Gautier, J. C., Azoulay, D., Kiffel, L., Belloc, C., Guengerich, F. P., Maurel, P., Beaune, P., and Leroux, J. P. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver, 827
- Leonard, S., *see* Lin, L.-H., 941
- Leroux, J. P., *see* Lemoine, A., 827
- Levy, F. O., *see* Gudermann, T., 412
- Li, J., *see* Smith, S. S., 1
- Li, M., *see* Yasuda, R. P., 149
- Liehr, J. G., *see* Ashburn, S. P., 534
- Liggett, S. B., *see* Thomas, R. F., 343
- Lin, G., *see* Hildebrand, K. R., 23
- Lin, L.-H., Leonard, S., and Harris, R. A. Enflurane inhibits the function of mouse and human brain phosphatidylinositol-linked acetylcholine and serotonin receptors expressed in *Xenopus* oocytes, 941
- Liu, C., *see* Safrany, S. T., 499
- Lloyd, R. V., Shuster, L., and Mason, R. P. Reexamination of the microsomal transformation of *N*-hydroxynorcocaine to norcocaine nitroxide, 645
- Lock, E. A., *see* Perry, S. J., 660
- Lockhart, P., *see* Smith, R. A., 741
- Loechner, K. J., *see* Jancis, E. M., 51
- Loh, H. H., *see* Law, P. Y., 684
- Lopez-de-Brinas, E., *see* Fuhr, U., 191

- Lösel, W., *see* Kratwurst, D., 655
 Lovinger, D. M., *see* Harrison, N. L., 482
 Lubeck, M. D., *see* Chanda, P. K., 516
 Lucaites, V. L., *see* Wainscott, D. B., 419
 Luedtke, R. R., *see* Boundy, V. A., 666
 Lynch, Carl, III, *see* Pancrazio, J. J., 783
 Lynch, G., *see* Hall, R. A., 459

M

- Macfarlane, M., *see* Perry, S. J., 660
 Mahr, G., *see* Fuhr, U., 191
 Makriyannis, A., DiMeglio, C. M., DeJong, A. P., and El-Khateeb, S. Hallucinogenic receptor models: Interaction of imidazolium chloride with amphetamine analogs, 78
 Malmberg, Å., Jackson, D. M., Eriksson, A., and Mohell, N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D_{2A}, D_{2B}, and D₃ receptors, 749
 Manaut, F., *see* Fuhr, U., 191
 Manley, P. W., *see* Quast, U., 474
 Mantey, S., Frucht, H., Coy, D. H., and Jensen, R. T. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes, 762
 Manzoni, O., *see* Dumuis, A., 976
 Margiotta, J. F., *see* Gurantz, D., 807
 Marks, B., *see* Karolak, L., 37
 Martin, A. W., *see* Sullivan, D. M., 207
 Marullo, S., *see* Nantel, F., 548
 Mason, R. P., *see* Burkitt, M. J., 257
 Mason, R. P., *see* Lloyd, R. V., 645
 Massicotte, G., *see* Hall, R. A., 459
 Mathewes, S., *see* Smith, R. A., 741
 Mattei, M.-G., *see* Matthes, H., 313
 Matthes, H., Boschert, U., Amlaiky, N., Grailhe, R., Plassat, J.-L., Muscatelli, F., Mattei, M.-G., and Hen, R. Mouse 5-hydroxytryptamine_{6A} and 5-hydroxytryptamine_{6B} receptors define a new family of serotonin receptors: Cloning, functional expression, and chromosomal localization, 313
 Maurel, P., *see* Lemoine, A., 827
 Mauro, D. J., De Riel, J. K., Tallarida, R. J., and Sirover, M. A. Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells, 854
 McGregor, W. H., *see* Chanda, P. K., 516
 Medina, D. J., *see* Mellors, J. W., 11
 Medina, J. M., *see* Bolaños, J. P., 487
 Medzhiradsky, F., *see* Carter, B. D., 465
 Meecham, K. G., *see* Hunter, J. C., 595
 Mellors, J. W., Im, G.-j., Tramontano, E., Winkler, S. R., Medina, D. J., Dutschman, G. E., Bazmi, H. Z., Piras, G., Gonzalez, C. J., and Cheng, Y.-c. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl) imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150), 11
 Merchant, M., *see* Santostefano, M., 200
 Miledi, R., *see* Woodward, R. M., 609
 Miller, R. J., *see* Glaum, S. R., 965
 Milstien, S., *see* Sakai, N., 6
 Mimeault, M., Fournier, A., Fêthiere, J., and De Léan, A. Development of natriuretic peptide analogs selective for the atrial natriuretic factor-R_{1A} receptor subtype, 775
 Minchin, M. C. W., *see* Chanda, P. K., 516
 Mio, M., *see* Tasaka, K., 365
 Mizutani, S., *see* Chanda, P. K., 516
 Mocchetti, I., *see* Follesa, P., 132
 Moebius, F. F., Burrows, G. G., Striessnig, J., and Glossmann, H. Biochemical characterization of a 22-kDa high affinity antiischemic drug-binding polypeptide in the endoplasmic reticulum of

guinea pig liver: Potential common target for antiischemic drug action, 139

- Mohell, N., *see* Malmberg, Å., 749
 Molinoff, P. B., *see* Boundy, V. A., 666
 Molinoff, P. B., *see* Ferry, R. C., 726
 Monsma, F. J., Jr., Shen, Y., Ward, R. P., Hamblin, M. W., and Sibley, D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs, 320
 Moore, G. J., *see* Hollenberg, M. D., 921
 Moreau, J.-P., *see* Raynor, K., 838
 Morrison, V., *see* Santostefano, M., 200
 Motohashi, K., *see* Ohmori, S., 183
 Mouradian, M. M., *see* Horiuchi, A., 281
 Moy, J. A., *see* Chatterjee, T. K., 167
 Munshi, R., *see* DeBernardi, M. A., 451
 Muramatsu, I., *see* Nishio, M., 96
 Murphy, W. A., *see* Raynor, K., 838
 Murray, M., *see* Butler, A. M., 902
 Murtaugh, M. P., *see* Hildebrand, K. R., 23
 Murthy, L., *see* Kirkland, J. L., 709
 Muscatelli, F., *see* Matthes, H., 313

N

- Nahorski, S. R., *see* Safrany, S. T., 499
 Nakamura, K., *see* Aramori, I., 127
 Nakamura, T., *see* Ohmori, S., 183
 Nakanishi, S., *see* Aramori, I., 127
 Nakaya, N., *see* Tasaka, K., 365
 Nantel, F., Bonin, H., Emorine, L. J., Zilberfarb, V., Strosberg, A. D., Bouvier, M., and Marullo, S. The human β_3 -adrenergic receptor is resistant to short term agonist-promoted desensitization, 548
 Narahashi, T., *see* Salgado, V. L., 626
 Neidle, S., *see* Greenidge, P. A., 982
 Nelson, D. L., *see* Wainscott, D. B., 419
 Neubig, R. R., and Sklar, L. A. Subsecond modulation of formyl peptide-linked guanine nucleotide-binding proteins by guanosine 5'-O-(3-thio)triphosphate in permeabilized neutrophils, 734
 Neubig, R. R., *see* Graeser, D., 434
 Nirei, H., *see* Aramori, I., 127
 Niroomand, F., Bangert, M., Philipps, C., and Rauch, B. Muscarinic receptor-mediated inhibition of GDP-activated adenylyl cyclase suggests a direct interaction of inhibitory guanine nucleotide-binding proteins and adenylyl cyclase, 90
 Nishio, M., Tsukahara, H., Hiraoka, M., Sudo, M., Kigoshi, S., and Muramatsu, I. Calcium channel current in cultured rat mesangial cells, 96
 Nissen, J. S., *see* Wainscott, D. B., 419
 Niznik, H. B., *see* Demchyshyn, L. L., 894
 Nomura, Y., *see* Kaneda, T., 356
 North, R. A., *see* Yakel, J. L., 277
 Notsu, Y., *see* Aramori, I., 127
 Numann, R., *see* Ragsdale, D., 949

O

- Ohmori, S., Shirakawa, C., Motohashi, K., Yoshida, H., Abe, H., Nakamura, T., Horie, T., Kitagawa, H., Asaoka, K., Rikihisa, T., Kanakubo, Y., and Kitada, M. Purification from liver microsomes from untreated cynomolgus monkeys of cytochrome P450 closely related to human cytochrome P450 2B6, 183
 Onaran, H. O., Costa, T., and Rodbard, D. $\beta\gamma$ Subunits of guanine nucleotide-binding proteins and regulation of spontaneous receptor activity: Thermodynamic model for the interaction between receptors and guanine nucleotide-binding protein subunits, 245
 Ono, T., *see* Aramori, I., 127
 Oswald, R. E., *see* Coleman, B. A., 217
 Otterness, D. M., *see* Honchel, R., 878
 Oury-Donat, F., *see* Rinaldi-Carmona, M., 84

P

- Palmer, K. J., *see* Hadingham, K. L., 970
Palumbo, M., *see* De Isabella, P., 715
Pan, S.-S., *see* Yu, F., 863
Pan, S.-S., Yu, F., and Hipsheer, C. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells, 870
Pancrazio, J. J., Park, W. K., and Lynch, Carl, III. Inhalational anesthetic actions on voltage-gated ion currents of bovine adrenal chromaffin cells, 783
Panetta, R., *see* Demchyshyn, L. L., 894
Park, W. K., *see* Pancrazio, J. J., 783
Patel, Y. C., *see* Demchyshyn, L. L., 894
Pauwels, R., *see* Debyser, Z., 521
Perez-Perez, M.-J., *see* Balzarini, J., 109
Pernet, A. G., *see* Fuhr, U., 191
Perry, S. J., Schofield, M. A., Macfarlane, M., Lock, E. A., King, L. J., Gibson, G. G., and Goldfarb, P. S. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate β -lyase, 660
Peters, W. P., *see* Karolak, L., 37
Petros, W. P., *see* Karolak, L., 37
Pfunder, H., *see* Clement, B., 335
Philipps, C., *see* Niroomand, F., 90
Piggot, J., *see* Smith, R. A., 741
Piras, G., *see* Mellors, J. W., 11
Plassat, J.-L., *see* Matthes, H., 313
Polenzani, L., *see* Woodward, R. M., 609
Potter, B. V. L., *see* Safrany, S. T., 499
Pregenzer, J. F., Im, W. B., Carter, D. B., and Thomsen, D. R. Comparison of interactions of [3 H]muscimol, *t*-butylbicyclophosphorothionate, and [3 H]flunitrazepam with cloned γ -aminobutyric acid_A receptors of the $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_2$ subtypes, 801
Prézeau, L., *see* Dumuis, A., 976
Pritchard, M. C., *see* Hunter, J. C., 595
Pritchett, D. B., *see* Szele, F. G., 915

Q

- Quast, U., Bray, K. M., Andres, H., Manley, P. W., Baumlin, Y., and Dosogne, J. Binding of the K⁺ channel opener [3 H]P1075 in rat isolated aorta: Relationship to functional effects of openers and blockers, 474
Quattrochi, L. C., and Tukey, R. H. Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: transcriptional activation of the human *CYP1A1* gene, 504

R

- Radke, H. K., *see* Harrison, N. L., 482
Ragan, C. I., *see* Hadingham, K. L., 970
Ragsdale, D., Numann, R., Catterall, W. A., and Scheuer, T. Inhibition of Na⁺ channels by the novel blocker PD85,639, 949
Rahman, A., *see* Rohlf, C., 372
Rauch, B., *see* Niroomand, F., 90
Raynor, K., Murphy, W. A., Coy, D. H., Taylor, J. E., Moreau, J.-P., Yasuda, K., Bell, G. I., and Reisine, T. Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides, 838
Reardon, I. M., *see* Wilborn, T. W., 70
Regunathan, S., *see* Wang, H., 509
Reilly, Y., *see* Chanda, P. K., 516
Reis, D. J., *see* Wang, H., 509
Reisine, T., *see* Raynor, K., 838
Rommel, R. P., *see* Ebner, T., 649
Renton, K. W., *see* Armstrong, S. G., 542
Reppert, S. M., *see* Yakel, J. L., 277
Richfield, E. K. Zinc modulation of drug binding, cocaine affinity states, and dopamine uptake on the dopamine uptake complex, 100

- Rikihisa, T., *see* Ohmori, S., 183
Rinaldi-Carmona, M., Congy, C., Simiand, J., Oury-Donat, F., Soubrie, P., Breliere, J. C., and Le Fur, G. Repeated administration of SR 46349B, a selective 5-hydroxytryptamine₂ antagonist up-regulates 5-hydroxytryptamine₂ receptors in mouse brain, 84
Ring, P. C., Seldon, P. M., Barnes, P. J., and Giembycz, M. A. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3 H] Apafant, a selective and competitive platelet-activating factor antagonist: Evidence that the noncompetitive behavior of Apafant in functional studies relates to slow kinetics of dissociation, 302
Roberts, J. D., *see* Bebenek, K., 57
Rodbard, D., *see* Onaran, H. O., 245
Rohlf, C., Safa, B., Rahman, A., Cho-Chung, Y. S., Klecker, R. W., and Glazer, R. I. Reversal of resistance of Adriamycin by 8-chlorocyclic AMP in Adriamycin-resistant HL-60 leukemia cells is associated with reduction of type I cyclic AMP-dependent protein kinase and cyclic AMP response element-binding protein DNA-binding activities, 372
Romanin, C., *see* Lakitsch, M., 293
Rosenberg, J. M., and Sato, P. H. Cisplatin inhibits *in vitro* translation by preventing the formation of complete initiation complex, 491
Roth, B. L., *see* Choudhary, M. S., 755
Rowe, T. C., *see* Sullivan, D. M., 207
Rubin, R. P., *see* Conway, B. R., 286
Rudnick, G., *see* Wall, S. C., 264
Rudnick, G., and Wall, S. C. Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters, 271
Ruggiero, D. A., *see* Wang, H., 509

S

- Saederup, E., *see* Squires, R. F., 795
Safa, B., *see* Rohlf, C., 372
Safe, S. H., *see* Santostefano, M., 200
Safrany, S. T., Wilcox, R. A., Liu, C., Dubreuil, D., Potter, B. V. L., and Nahorski, S. R. Identification of partial agonists with low intrinsic activity at the inositol 1,4,5-trisphosphate receptor, 499
Saifeddine, M., *see* Hollenberg, M. D., 921
Sakai, N., Kaufman, S., and Milstien, S. Tetrahydrobiopterin is required for cytokine-induced nitric oxide production in a murine macrophage cell line (RAW 264), 6
Salari, H., *see* Burt, H. M., 30
Salgado, V. L., and Narahashi, T. Immobilization of sodium channel gating charge in crayfish giant axons by the insecticide fenvalerate, 626
San-Felix, A., *see* Balzarini, J., 109
Santostefano, M., Merchant, M., Arellano, L., Morrison, V., Denison, M. S., and Safe, S. H. α -Naphthoflavone-induced *CYP1A1* gene expression and cytosolic aryl hydrocarbon receptor transformation, 200
Sanz, F., *see* Fuhr, U., 191
Satkus, S. A., *see* Yasuda, R. P., 149
Sato, P. H., *see* Rosenberg, J. M., 491
Sausen, P. J., Duescher, R. J., and Elfarra, A. A. Further characterization and purification of the flavin-dependent *S*-benzyl-L-cysteine *S*-oxidase activities of rat liver and kidney microsomes, 388
Savchenko, A., *see* Hering, S., 820
Schenck, K. W., *see* Wainscott, D. B., 419
Scheuer, T., *see* Ragsdale, D., 949
Schindler, H., *see* Lakitsch, M., 293
Schofield, M. A., *see* Perry, S. J., 660
Schuetz, E. G., *see* Kocarek, T. A., 328
Schultz, G., *see* Kratwurst, D., 655
Schulz, R., *see* Ammer, H., 556
Schunack, W., *see* Sinkins, W. G., 569
Schwartz, R. D., *see* Thomsen, W., 955
Sebben, M., *see* Dumuis, A., 976

- Seeman, P., *see* Demchyshyn, L. L., 894
 Seldon, P. M., *see* Ring, P. C., 302
 Servant, G., Boulay, G., Bossé, R., Escher, E., and Guillemette, G. Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium, 677
 Shen, Y., *see* Monsma, F. J., Jr., 320
 Shih, J. C., *see* Wang, C.-D., 931
 Shih, J. C., *see* Wu, H.-F., 888
 Shimazawa, M., *see* Tasaka, K., 365
 Shirakawa, C., *see* Ohmori, S., 183
 Shoubo, M., *see* Aramori, I., 127
 Shuster, L., *see* Lloyd, R. V., 645
 Sibley, D. R., *see* Monsma, F. J., Jr., 320
 Silkworth, J. B., *see* Fasco, M. J., 226
 Simiand, J., *see* Rinaldi-Carmona, M., 84
 Sinkins, W. G., and Wells, J. W. G protein-linked receptors labeled by [³H]histamine in guinea pig cerebral cortex. II. Mechanistic basis for multiple states of affinity, 583
 Sinkins, W. G., Kandel, M., Kandel, S. I., Schunack, W., and Wells, J. W. G protein-linked receptors labeled by [³H]histamine in guinea pig cerebral cortex. I. Pharmacological characterization, 569
 Sirover, M. A., *see* Mauro, D., J., 854
 Sisk, R., *see* Smith, R. A., 741
 Sissi, C., *see* De Isabella, P., 715
 Sklar, L. A., *see* Neubig, R. R., 734
 Smith, R. A., Sisk, R., Lockhart, P., Mathewes, S., Gilbert, T., Walker, K., and Piggot, J. Isolation of glucagon antagonists by random molecular mutagenesis and screening, 741
 Smith, S. S., and Li, J. Novel action of nitric oxide as mediator of *N*-methyl-D-aspartate-induced phosphatidylinositol hydrolysis in neonatal rat cerebellum, 1
 Sogabe, K., *see* Aramori, I., 127
 Sörgel, F., *see* Fuhr, U., 191
 Soubrie, P., *see* Rinaldi-Carmona, M., 84
 Spagnola, B. V., *see* Yasuda, R. P., 149
 Squires, R. F., and Saederup, E. Indomethacin/ibuprofen-like anti-inflammatory agents selectively potentiate the γ -aminobutyric acid-antagonistic effects of several norfloxacin-like quinolone antibacterial agents on [³⁵S]t-butylbicyclophosphorothionate binding, 795
 Srikant, C. B., *see* Demchyshyn, L. L., 894
 Staib, A. H., *see* Fuhr, U., 191
 Stancel, G. M., *see* Kirkland, J. L., 709
 Steel, M. C., and Buckley, N. J. Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: A comparative polymerase chain reaction study, 694
 Stickle, D. F., and Barber, R. Analysis of receptor-mediated activation of GTP-binding protein/adenylate cyclase using the encounter coupling model, 397
 Storm, C., *see* Gao, W.-Y., 45
 Strandberg, B., *see* Debyser, Z., 521
 Striessnig, J., *see* Hering, S., 820
 Striessnig, J., *see* Lakitsch, M., 293
 Striessnig, J., *see* Moebius, F. F., 139
 Strobl, G., *see* Fuhr, U., 191
 Strosberg, A. D., *see* Nantel, F., 548
 Strübing, C., *see* Hering, S., 820
 Stuart, J. E., *see* Ciaccio, P. J., 845
 Sudo, M., *see* Nishio, M., 96
 Sullivan, D. M., Eskildsen, L. A., Groom, K. R., Webb, C. D., Latham, M. D., Martin, A. W., Wellhausen, S. R., Kroeger, P. E., and Rowe, T. C. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistance Chinese hamster ovary cell line, 207
 Suman-Chauhan, N., *see* Hunter, J. C., 595
 Sunahara, R. K., *see* Demchyshyn, L. L., 894
 Szele, F. G., and Pritchett, D. B. High affinity agonist binding to cloned 5-hydroxytryptamine₂ receptors is not sensitive to GTP analogs, 915
 Szumlanski, C., *see* Honchel, R., 878
- T**
- Takeyasu, K., *see* Horiuchi, A., 281
 Tallarida, R. J., *see* Mauro, D. J., 854
 Tamkun, M. M., *see* Harrison, N. L., 482
 Tasaka, K., Mio, M., Shimazawa, M., and Nakaya, N. Histamine-induced production of interleukin-1 α from murine bone marrow stromal cells and its inhibition by H₂ blockers, 365
 Taupin, V., Gogusev, J., Descamps-Latscha, B., and Zavala, F. Modulation of tumor necrosis factor- α , interleukin-1 β , interleukin-6, interleukin-8, and granulocyte/macrophage colony-stimulating factor expression in human monocytes by an endogenous anxiogenic benzodiazepine ligand, triakontatetraneuropeptide: Evidence for a role of prostaglandins, 64
 Taylor, D. A., *see* Hershman, K. M., 833
 Taylor, J. E., *see* Raynor, K., 838
 Tew, K. D., *see* Ciaccio, P. J., 845
 Thomas, D. C., *see* Bebenek, K., 57
 Thomas, R. F., and Liggett, S. B. Lack of β_3 -adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human, 343
 Thomsen, D. R., *see* Pregenzer, J. F., 801
 Thomsen, W., Hays, S. J., Hicks, J. L., Schwartz, R. D., and Catterall, W. A. Specific binding of the novel Na⁺ channel blocker PD85,639 to the α subunit of the rat brain rat Na⁺ channels, 955
 Thurman, R. G., *see* Bradford, B. U., 115
 Topar, G., *see* Lakitsch, M., 293
 Tramontano, E., *see* Mellors, J. W., 11
 Tsukahara, H., *see* Nishio, M., 96
 Tukey, R. H., *see* Quattrochi, L. C., 504
- U**
- Ullrich, V., *see* Wu, X.-B., 564
 Unsworth, C. D., *see* Ferry, R. C., 726
- V**
- Van Tol, M., *see* Demchyshyn, L. L., 894
 Veale, M. A., *see* Williams, R. J., 158
 Velazquez, S., *see* Balzarini, J., 109
 von Appen, F., *see* Wu, X.-B., 564
- W**
- Wafford, K. A., Whiting, P. J., and Kemp, J. A. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant γ -aminobutyric acid_A receptor subtypes, 240
 Wainscott, D. B., Cohen, M. L., Schenck, K. W., Audia, J. E., Nissen, J. S., Baez, M., Kursar, J. D., Lucaites, V. L., and Nelson, D. L. Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine_{2F} receptor, 419
 Walker, K., *see* Smith, R. A., 741
 Wall, S. C., Innis, R. B., and Rudnick, G. Binding of the cocaine analog 2 β -carbomethoxy-3 β -(4-[¹²⁵I]iodophenyl)tropane to serotonin and dopamine transporters: Different ionic requirements for substrate and 2 β -carbomethoxy-3 β -(4-[¹²⁵I]iodophenyl) tropane binding, 264
 Wall, S. C., *see* Rudnick, G., 271
 Wall, S. J., *see* Yasuda, R. P., 149
 Wang, C.-D., Gallaher, T. K., and Shih, J. C. Site-directed mutagenesis of the serotonin 5-hydroxytryptamine₂ receptor: Identification of amino acids necessary for ligand binding and receptor activation, 931
 Wang, H., Regunathan, S., Ruggiero, D. A., and Reis, D. J. Production and characterization of antibodies specific for the imidazoline receptor protein, 509
 Ward, R. P., *see* Monsma, F. J., Jr., 320

- Warren, R. A., *see* Yakel, J. L., 277
- Webb, C. D., *see* Sullivan, D. M., 207
- Weinshank, R. L., *see* Adham, N., 427
- Weinshilboum, R. M., *see* Honchel, R., 878
- Weisstein, J. S., *see* Yasuda, R. P., 149
- Wellhausen, S. R., *see* Sullivan, D. M., 207
- Wells, J. W., *see* Sinkins, W. G., 569, 583
- Whiting, P. J., *see* Hadingham, K. L., 970
- Whiting, P. J., *see* Wafford, K. A., 240
- Wieben, E. D., *see* Honchel, R., 878
- Wilborn, T. W., Comer, K. A., Dooley, T. P., Reardon, I. M., Heinrikson, R. L., and Falany, C. N. Sequence analysis and expression of the cDNA for the phenol-sulfating form of human liver phenol sulfotransferase, 70
- Wilcox, R. A., *see* Safrany, S. T., 499
- Williams, R. J., Veale, M. A., Horne, P., and Kelly, E. Ethanol differentially regulates guanine nucleotide-binding protein α subunit expression in NG108-15 cells independently of extracellular adenosine, 158
- Wingrove, P., *see* Hadingham, K. L., 970
- Winkler, S. R., *see* Mellors, J. W., 11
- Withiam-Leitch, M., *see* Conway, B. R., 286
- Wolfe, B. B., *see* Yasuda, R. P., 149
- Wolfe, M. S., *see* Ault-Riché, D. B., 989
- Wood, T. C., *see* Honchel, R., 878
- Woodruff, G. N., *see* Hunter, J. C., 595
- Woodward, R. M., Polenzani, L., and Miledi, R. Characterization of bicuculline/baclofen-insensitive (ρ -like) γ -aminobutyric acid receptors expressed in *Xenopus* oocytes. II. Pharmacology of γ -aminobutyric acid_A and γ -aminobutyric acid_B receptor agonists and antagonists, 609
- Wu, H.-F., Chen, K., and Shih, J. C. Site-directed mutagenesis of monoamine oxidase A and B: Role of cysteines, 888
- Wu, X.-B., Brüne, B., von Appen, F., and Ullrich, V. Efflux of cyclic GMP from activated human platelets, 564
- Y**
- Yakel, J. L., Warren, R. A., Reppert, S. M., and North, R. A. Functional expression of adenosine A_{2B} receptor in *Xenopus* oocytes, 277
- Yasuda, K., *see* Raynor, K., 838
- Yasuda, R. P., Ciesla, W., Flores, L. R., Wall, S. J., Li, M., Satkua, S. A., Weisstein, J. S., Spagnola, B. V., and Wolfe, B. B. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: Distribution of m4 and m5 receptors in rat brain, 149
- Yoshida, H., *see* Ohmori, S., 183
- Yu, F., and Pan, S.-S. Effect of pH on DNA alkylation by enzyme-activated mitomycin C and porfiromycin, 863
- Yu, F., *see* Pan, S.-S., 863
- Yuan, C.-S., *see* Ault-Riché, D. B., 989
- Z**
- Zavala, F., *see* Taupin, V., 64
- Zilberfarb, V., *see* Nantel, F., 548
- Zinn, S., *see* Chu, E., 527
- Zunino, F., *see* De Isabella, P., 715

SUBJECT INDEX FOR VOLUME 43

A

- Acetylcholinesterase, catalytic subunit, benzomorphan opiate binding site, 217
- Adenosine, extracellular, ethanol effects on G protein expression, NG108-15 cells, 158
- Adenosine monophosphate, cyclic
histamine-induced production of IL-1 α , inhibition by H₂ blockers, bone marrow stromal cells (mouse), 365
phosphodiesterase activities, δ -opioid receptor, activation of NG108-15 cells, 684
reversal of resistance to Adriamycin, 8-chloro-cyclic AMP, HL-60 cells, 372
- Adenosine triphosphate, receptor-activated nonselective cation channels, potent inhibitor, HL-60 cells, 655
- S-Adenosyl-L-homocysteine, metabolism in murine L929 cells, 4'-modified analogs, aristeromycin, 989
- Adenylate cyclase-GTP-binding protein, receptor-mediated activation, encounter coupling method, 397
- Adenylyl cyclase, GDP-activated, muscarinic receptor-mediated inhibition, carbachol (dog), 90
- Adipose tissue, lack of β_3 -adrenergic receptor mRNA expression (human), 343
- Adrenal gland
chromaffin cells, voltage-gated ion currents, inhalational anesthetic actions, 783
steroids and β -adrenergic receptor activation, basic fibroblast growth factor and nerve growth factor mRNA, central nervous system (rat), 132
- Adrenoceptors
alpha-2
compartmentation, guanine nucleotide-binding proteins in NG108-15 cells, 434
molecular characterization, intestinal electrolyte transport (pig), 23
subtype-specific antibodies, 444
beta
activation of GTP-binding protein/adenylate cyclase, encounter coupling method, 397
cAMP accumulation inhibited by Ca²⁺, C6-2B glioma cells (rat), 451
trophic factor regulation (rat), 132
beta-3
lack of receptor mRNA expression, adipose and other metabolic tissues (human), 343
resistance, short-term agonist-promoted desensitization, 548
- Adriamycin, reversal of resistance by 8-chloro-cyclic AMP, multidrug resistance, HL-60 cells, 372
- Affinity, multiple states, protein-linked receptors labeled by histamine, cerebral cortex (guinea pig), 583
- Agonists, chronic exposure, muscarinic receptor mRNA levels, neuroblastoma cells, 694
- Albumin, modulation, neuronal cholinergic sensitivity (chick), 807
- Alcohol dehydrogenase, inhibition of fatty acyl coenzyme synthetase, 4-methylpyrazole, catalase-dependent alcohol metabolism (mouse), 115
- Amino acids
ligand binding, site-directed mutagenesis, 5-HT₂ receptor, 931
substitution in reverse transcriptase of HIV-1, resistance to TIBO R82150, 11

 γ -Aminobutyric acid

- antagonistic effects, norfloxacin-like quinolone antibacterial agents, potentiation by indomethacin/ibuprofen-like anti-inflammatory agents (rat), 795
stimulation of shunt, valproate and *E*- Δ^2 -valproate, neonatal brain (rat), 487
- DL- α -Amino-3-hydroxy-5-methylisoxazolepropionic acid, receptor states, increase in affinity, thiocyanate (rat), 459
- Amphetamine, non-neurotoxic derivatives, serotonin release, serotonin transporters (human), 271
- Amphetamine analogs, interaction of imidazolium chloride, hallucinogenic receptor models, 78
- Anesthetics
inhalational, voltage-gated ion currents, bovine adrenal chromaffin cells, 783
PD85,639, inhibition of Na⁺ channels, 949
- Angiotensin II, signaling mechanism, neuroblastoma Neuro-2A cells, soluble guanylyl cyclase, 603
- Antagonists, agonists and partial agonists, regulation of 5-HT₂ receptors, P11 cells, 726
- Antibacterial agents, norfloxacin-like quinolone, GABA-antagonistic effects, indomethacin/ibuprofen-like anti-inflammatory agents (rat), 795
- Antibodies, subtype-specific, α_2 -adrenergic receptor, 444
- Anti-inflammatory agents, indomethacin/ibuprofen-like, GABA-antagonistic effects, norfloxacin-like quinolone antibacterial agents (rat), 795
- Antipsychotic agents, binding characteristics, dopamine D_{2A}/D_{2B}/D₃ receptors (human), 749
- Antisera, m4 and m5 muscarinic cholinergic receptors, distribution in brain (rat), 149
- Aorta, binding of K⁺ channel opener [³H]P1075 (rat), 474
- Apafant, pharmacological characterization, platelet-activating factor receptor, peritoneal macrophages (guinea pig), 302
- Arachidonic acid, release, stimulation of glutamate receptors, Na⁺/Ca²⁺ exchanger in neuronal cells, 976
- Aristeromycin, 4'-modified analogs, S-adenosyl-L-homocysteine, L929 cells, 989
- Aryl hydrocarbon, receptor transformation, α -naphthoflavone-induced CYP1A1 gene expression (rat), 200
- Atrial natriuretic factor-R_{1A} receptor subtype, development, natriuretic peptide analogs, 775
- Axons, giant, immobilization of sodium channel gating charge, fenvalerate (crayfish), 626
- 3'-Azido-3'-deoxythymidine, metabolites, simian virus 40 origin-dependent replication, HeLa cell extracts, 57

B

- Baclofen-bicuculline-insensitive GABA receptors, *Xenopus* oocytes, 609
- Bay K 8644, calcium channel current, cultured mesangial cells (rat), 96
- Benzamides, antipsychotic agents, binding characteristics, dopamine F_{2A}D_{2B}D₃ receptors (human), 749
- Benzamidine, N-hydroxylation to benzamidoximine, cytochrome P-450 oxidase system, liver (rabbit), 335
- Benzodiazepines, ligand triakontatetrapeptide, cytokine modulation of role of prostaglandins, monocytes (human), 64
- Benzomorphan, opiate binding site, catalytic subunit, acetylcholinesterase, 217

- Benzothiazepine, binding domain, extracellular localization, L-type Ca^{2+} channels (rabbit), 820
- S-Benzyl-L-cysteine S-oxidase, flavin-dependent, activities of liver and kidney microsomes (rat), 388
- Bicuculline-baclofen-insensitive GABA receptors, *Xenopus* oocytes, 609
- Bilirubin, UDP-glucuronosyltransferase, glucuronidation of ethinyl-estradiol (human), 649
- 1,3-Bis(2-chloroethyl)-1-nitrosourea, high-dose chemotherapy-induced platelet defect, inhibition, platelet signal transduction pathways, 37
- Bombesin, receptor subtypes, radiolabeled antagonists (guinea pig), 762
- Bone marrow, stromal cells, histamine-induced production of IL-1 α , inhibition by H_2 blockers (mouse), 365
- Brain
- antibodies, imidazoline receptor protein, 509
 - chromosomal localization and functional expression, cloning, 5-HT $_{1A}$ and 5-HT $_{1B}$ receptors (mouse), 313
 - development of antisera, m4 and m5 muscarinic cholinergic receptors (rat), 149
 - high affinity agonist binding, cloned 5-HT $_2$ receptors (human), 915
 - Na^+ channels, specific binding of PD85,639 (rat), 955
 - neonatal, stimulation of GABA shunt, valproate and E - Δ^2 -valproate (rat), 487
 - nucleus tractus solitarius, metabotropic glutamate receptor activation, zinc protoporphyrin-IX (rat), 965
 - phosphatidylinositol-linked acetylcholine and serotonin receptors, inhibition of function, enflurane (mouse, human), 941
 - solubilization of cannabinoid receptor, interaction, guanine nucleotide-binding proteins (rat), 17
 - up-regulation of 5-HT $_2$ receptors, SR 46349B (mouse), 84
- t*-Butylbicyclophosphorothionate
- muscimol and flunitrazepam, interactions with GABA $_A$ receptors, 801
 - norfloxacin-like quinolone antibacterial agents, GABA-antagonistic effects, indomethacin/ibuprofen-like anti-inflammatory agents (rat), 795
- C**
- Calcitonin gene-related peptide, receptor, guanine nucleotide-sensitive form, solubilization (rat, human), 167
- Calcium
- activation of cAMP phosphodiesterase activities, δ -opioid receptor, NG108-15 cells, 684
 - cytoplasmic concentration, m3 subtype muscarinic acetylcholine receptors, Jurkat cells, 356
 - functional expression, adenosine A_{2A} receptor, *Xenopus* oocytes, 277
 - inhibition of β -adrenergic- and forskolin-stimulated cAMP accumulation, C6-2B glioma cells (rat), 451
 - voltage-gated ion currents, inhalational anesthetic actions, bovine adrenal chromaffin cells, 783
- Calcium channels
- current in cultured mesangial cells (rat), 96
 - L-type, extracellular localization, benzothiazepine binding domain (rabbit), 820
 - L-type α_1 subunits, heterogeneity, discrimination by 1,4-dihydropyridine B 874-67, 293
 - signaling of angiotensin II, Neuro-2A cells, 603
- Carbachol, muscarinic receptor-mediated inhibition, GDP-activated adenylyl cyclase (dog), 90
- 2 β -Carbomethoxy-3 β -(4-[125 I]iodophenyl)tropane, binding to serotonin and dopamine transporters, ionic requirements, 264
- Carcinogenesis, hormonal, catechol estrogens, microsomal hydroxylation (hamster), 534
- Carcinoma, colonic, molecular cloning and expression, thiopurine methyltransferase (human), 878
- Carcinoma, colorectal, cloning of *Escherichia coli* cytosine deaminase, first step, development of gene therapy, 380
- Catechol, estrogens, hormonal carcinogenesis, microsomal hydroxylation (hamster), 534
- Cation channels, receptor-activated nonselective, potent inhibitor, HL-60 cells, 655
- Central nervous system, tropic factor regulation (rat), 132
- Cerebellar granule cells, paradoxical increase, 5-HT $_2$ receptors, 5-HT $_2$ receptor mRNA (rat), 349
- Cerebellum, neonatal, nitric oxide as mediator, NMDA-induced phosphatidylinositol hydrolysis (rat), 1
- Cerebral cortex
- antagonist radioligand [^3H]PD 140376, cholecystokinin $_B$ /gastrin receptor (guinea pig), 595
 - G protein-linked receptors, [^3H]histamine receptors (guinea pig), 569, 583
- CGS 21680, adenosine A_2 receptor subtypes, erythroleukemia cells and platelets (human), 909
- Chemotherapy, high-dose, induced platelet defect (human), 37
- Chinese hamster ovary cells
- inhibition of Na^+ channels, PD85,639, 949
 - subtype selectivity of FR139317, 127
- topoisomerase II activity, cleavage of DNA, multidrug resistance, 207
- Chloride, functional expression, adenosine A_{2A} receptor, *Xenopus* oocytes, 277
- 8-Chloro-cyclic AMP, reversal of resistance to Adriamycin, HL-60 cells, 372
- Chromaffin cells, adrenal, inhalational anesthetic actions, 783
- Chromosome 20, cloning and expression, somatostatin 14-selective receptor variant (human), 894
- Chromosomes, localization and functional expression, cloning, 5-HT $_{1A}$ and 5-HT $_{1B}$ receptors (mouse), 313
- Cisplatin, inhibition of *in vitro* translation, prevention of formation, complete initiation complex (rabbit), 491
- Clozapine, antipsychotic agents, binding characteristics, dopamine $D_{2A}D_{2B}D_3$ receptors (human), 749
- Cocaine
- affinity states, zinc modulation of drug binding, dopamine uptake complex (rat), 100
 - analog binding to serotonin and dopamine transporters, ionic requirements, 264
 - microsomal transformation, *N*-hydroxynorcocaine to norcocaine nitroxide, 645
- Colon
- ethacrynic acid-resistant cells, overproduction, 37.5-kDa cytosolic protein (human), 845
 - neoplasms, thymidylate synthase regulation, 5-fluorouracil and interferon- γ (human), 527
- Colony-stimulating factor, granulocyte/macrophage, modulation by triakontatetrapeptide and role of prostaglandins, monocytes (human), 64
- Cyclic AMP, *see* Adenosine monophosphate, cyclic
- Cyclic GMP, *see* Guanosine monophosphate, cyclic
- Cysteines
- conjugate β -lyase, cDNA coding, kidney (rat), 660
 - site-directed mutagenesis, monoamine oxidase A and B (human), 888
- Cytochrome P-450
- 1A2 and 3A4, major pathway of imipramine metabolism, liver (human), 827
 - 2C, substrate correlation with primary structure, warfarin as probe (human), 234
 - constitutive, inhibition and inactivation by parathion, liver (rat), 902
 - N*-dealkylation of propafenone, molecular base for interaction (human), 120

Cytochrome P-450—continued

- hepatic, mechanism of modulation, *Listeria monocytogenes* infection (mouse), 542
- messenger RNAs in primary cultures, expression of multiple forms, hepatocytes maintained on Matrigel (rat), 328
- purification from untreated Cynomolgus monkeys, close relationship, human cytochrome P450 2B6, 183
- small intestine, probed by warfarin metabolism (rat), 226
- Cytochrome P-450 oxidase, *N*-hydroxylation of benzamidine to benzamidoimine, liver (rabbit), 335
- Cytokine-induced nitric oxide production, tetrahydrobiopterin, macrophage cell line (mouse), 6
- Cytoplasm, increases in Ca^{2+} concentration, m3 subtype muscarinic acetylcholine receptors, Jurkat cells, 356
- Cytosine deaminase, *Escherichia coli*, development of gene therapy, colorectal carcinoma, 380
- Cytosol
 - aryl hydrocarbon receptor transformation, α -naphthoflavone-induced *CYP1A1* gene expression (rat), 200
 - cysteine conjugate β -lyase, cDNA coding, kidney (rat), 660
 - overproduction of 37.5-kDa protein, prostaglandin F synthase, ethacrynic acid-resistant colon cells (human), 845

D

- Desensitization, agonist-promoted, human β_3 -adrenergic receptor, resistance (hamster), 548
- Desferrioxamine, paraquat and, electron spin resonance spin-trapping, acute iron poisoning (rat), 257
- 1,4-Dihydropyridine B 874-67, heterogeneity of L-type calcium channel α_1 subunits, 293
- Diltiazem, extracellular localization, benzothiazepine binding domain, L-type Ca^{2+} channels (rabbit), 820
- Dioxin, nuclear uptake of Ah receptor, omeprazole (human), 504
- DNA
 - alkylation, effect of pH, enzyme-activated mitomycin C and porfomycin, 863
 - first step in development of gene therapy, cloning and expression, *Escherichia coli* cytosine deaminase, 380
 - minor groove recognition properties, pentamidine and its analogs, molecular modeling study, 982
 - mitomycin C-induced damage, enzymatic and pH modulation, HCT 116 cells, 870
- DNA, complementary
 - antisense, protein kinase Ca , attenuation of resistance in MCF-7 cells, 858
 - cloning of sequences, α_2 and α_3 GABA $_A$ receptor subunits (human), 970
 - coding for kidney cytosolic cysteine conjugate β -lyase (rat), 660
 - phenol-sulfating form, liver phenol sulfotransferase (human), 70
 - 8784 colon carcinoma cells, molecular cloning and expression, thiopurine methyltransferase (human), 878
- DNA glycolase, uracil, mechanisms of 5-fluorouracil excision, normal cells (human), 854
- DNA topoisomerase II, cleavage of DNA into topological domains, alteration, multidrug-resistant CHO cells, 207
- Dopamine
 - transporters, binding of cocaine analog, ionic requirements, 264
 - uptake complex, zinc modulation of drug binding, cocaine affinity states (rat), 100
- Doxorubicin-resistant MCF-7 cells, attenuation of resistance, antisense cDNA for protein kinase Ca , 858
- Drug resistance, resistance to TIBO R82150, single conservative amino acid substitution, reverse transcriptase of HIV-1, 11

E

- Electrolytes, intestinal transport, molecular characterization, α_2 -adrenergic receptors (pig), 23

- Electron spin resonance spin-trapping, hydroxyl radical generation, paraquat and desferrioxamine, acute iron poisoning (rat), 257
- Endoplasmic reticulum, 22-kDa high affinity antiischemic drug-binding polypeptide, liver (guinea pig), 139
- Endothelin, antagonist FR139317, subtype selectivity, transfected Chinese hamster ovary cells, 127
- Endothelium, vascular, amino- and carboxyl-terminal domains, thrombin receptor-derived polypeptides (guinea pig), 921
- Enflurane, inhibition of phosphatidylinositol-linked acetylcholine and serotonin receptors, *Xenopus* oocytes, brain (mouse, human), 941
- Enzyme
 - activated mitomycin C and porfomycin, effect of pH, DNA alkylation, 863
 - pH modulation and, mitomycin C-induced DNA damage, HCT 116 cells, 870
- Erythroleukemia cells, platelets and, adenosine receptors (human), 909
- Estradiol, induction of rhodamine 123 efflux, multidrug resistance pump, pituitary tumor cells (rat), 51
- Estrogens, catechol, hormonal carcinogenesis, microsomal hydroxylation (hamster), 534
- Ethacrynic acid-resistant colon cells, overproduction, 37.5-kDa cytosolic protein (human), 845
- Ethanol, differential regulation, guanine nucleotide-binding protein α subunit, NG108-15 cells, 158
- Ethinylestradiol, glucuronidation, bilirubin UDP-glucuronosyltransferase (human), 649

F

- Fatty acyl coenzyme synthetase, inhibition by 4-methylpyrazole, catalase-dependent alcohol metabolism (mouse), 115
- Fenvalerate, immobilization of sodium channel gating charge, giant axons (crayfish), 626
- Fibroblast growth factor, basic, regulation of mRNA by β -adrenergic receptor activation, central nervous system (rat), 132
- Fibroblasts, Chinese hamster, human β_3 -adrenergic receptor, resistance to agonist-promoted desensitization, 548
- Flavin-dependent *S*-benzyl-L-cysteine *S*-oxidase, activities of liver and kidney microsomes (rat), 388
- Flunitrazepam, muscimol and *t*-butylbicyclopophospho[^{35}S]thionate, interactions with GABA $_A$ receptors, 801
- 5-Fluoro-2'-deoxyuridine, resistance, variation in thymidylate synthase (human), 702
- 2-Fluoroestradiol, microsomal hydroxylation, catechol estrogens, hormonal carcinogenesis (hamster), 534
- 5-Fluorouracil
 - interferon- γ and, regulation of thymidylate synthase, colon cancer cells (human), 527
 - mechanisms of excision, uracil DNA glycolase, normal cells (human), 854
- FMLP, receptor-activated nonselective cation channels, potent inhibitor, HL-60 cells, 655
- Formyl peptide-linked guanine nucleotide-binding proteins, sub-second modulation, guanosine 5'-*O*-(3-thio)triphosphate in neutrophils (human), 734
- FR139317, subtype selectivity, transfected Chinese hamster ovary cells, 127

G

- Gastric mucosa, antagonist radioligand [^3H]PD 140376, cholecystokinin $_B$ /gastrin receptor (guinea pig), 595
- GDP-activated adenyl cyclase, muscarinic receptor-mediated inhibition (dog), 90

Gene

CYP1A1

- induction by α -naphthoflavone, cytosolic aryl hydrocarbon receptor transformation (rat), 200
- nuclear uptake of Ah (dioxin) receptor, omeprazole (human), 504

- imidazoline receptor protein, specific antibodies, 509
 therapy development, cloning of *Escherichia coli* cytosine deaminase, colorectal carcinoma, 380
 Glioma, β -adrenergic receptor- and forskolin-stimulated cAMP accumulation, inhibition by Ca^{2+} (rat), 451
 Glucagon, antagonists, random mutagenesis and screening (rat), 741
 Glucocorticoids, inhibition of formation of IL-1/IL-1 β /IL-6, mediation, decreased mRNA stability (human), 176
 G proteins
 α subunit, differential regulation by ethanol, NG108-15 cells, 158
 $\beta\gamma$ subunits, regulation, spontaneous receptor activity, 245
 activation of cAMP phosphodiesterase activities, α -opioid receptor, NG108-15 cells, 684
 -adenylate cyclase, receptor-mediated activation, encounter coupling method, 397
 compartmentation of receptors, NG108-15 cells, 434
 formyl peptide-linked, subsecond modulation, 5'-O-(3-thio)-triphosphate in neutrophils (human), 734
 G_{α} , coupling of prostaglandin E₁ receptors, NG108-15 cells, 556
 -linked receptors labeled by [³H]histamine, cerebral cortex (guinea pig), 569, 583
 muscarinic receptor-mediated inhibition, GDP-activated adenylyl cyclase (dog), 90
 polyclonal anti-D2 dopamine receptor antibodies, development of, sequence-specific peptides, 666
 -sensitive form, calcitonin gene-related peptide receptor, solubilization (rat, human), 167
 solubilization of cannabinoid receptor, brain (rat), 17
 Guanosine monophosphate, cyclic, efflux from activated platelets (human), 564
 Guanosine 5'-O-(3-thio)triphosphate, subsecond modulation, formyl peptide-linked guanine nucleotide-binding proteins (human), 734
 Guanosine triphosphate, analogs, high affinity agonist binding, cloned 5-HT₂ receptors (human), 915
 Guanylyl cyclase, soluble, signaling of angiotensin II, Neuro-2A cells, 603

H

- Halothane, voltage-gated ion currents, bovine adrenal chromaffin cells, 783
 H₂ blockers, inhibition, histamine-induced production of IL-1 α , bone marrow stromal cells (mouse), 365
 HCT 116 cells, mitomycin C-induced DNA damage, enzymatic and pH modulation, 870
 HeLa cells, simian virus 40 origin-dependent replication, 3'-azido-3'-deoxythymidine metabolites, 57
 Hepatocytes, primary cultures maintained on Matrigel, expression of multiple forms, cytochrome P450 mRNAs (rat), 328
 Hippocampus
 modulation of gating, cloned K⁺ channels, micromolar Zn²⁺ (rat, human), 482
 neurons, NMDA receptor channels, potentiation by pregnenolone sulfate (rat), 813
 Histamine
 -induced production of interleukin 1 α , bone marrow stromal cells, inhibition by H₂ blockers (mouse), 365
 labeling of G protein-linked receptors, cerebral cortex (guinea pig), 569, 583
 HIV-1, see Human immunodeficiency virus-1
 HL-60 cells
 receptor-activated nonselective cation currents, potent inhibitor, 655
 reversal of resistance to Adriamycin, 8-chloro-cyclic AMP, 372
 Human immunodeficiency virus-1
 reverse transcriptases
 kinetics, resistance to inhibitors, 521
 resistance to TIBO R82150, single conservative amino acid substitution, 11
 -specific TSAO, resistance spectrum, 109

- Hydroxyl radicals, electron spin resonance spin-trapping, paraquat and desferrioxamine, acute iron poisoning (rat), 257
 N-Hydroxynorcocaine, microsomal transformation to norcocaine nitroxide, reexamination, 645

I

- Ibuprofen-like anti-inflammatory agents, GABA-antagonistic effects, norfloxacin-like quinolone antibacterial agents (rat), 795
 Imidazoline, receptor protein, specific antibodies, 509
 Imidazolium chloride, interaction with amphetamine analogs, hallucinogenic receptor models, 78
 Imipramine, major pathway of metabolism, cytochromes P-450 1A2 and P-450 3A4, liver (human), 827
 Indomethacin-ibuprofen-like anti-inflammatory agents, GABA-antagonistic effects, norfloxacin-like quinolone antibacterial agents (rat), 795
 Initiation complexes, prevention of formation, inhibition of *in vitro* translation, cisplatin (rabbit), 491
 Inositol-1,4,5-trisphosphate, receptor, low intrinsic activity, partial agonists, 499
 Insecticide, fenvalerate, immobilization of sodium channel gating charge, giant axons (crayfish), 626
 Interferon- γ , 5-fluorouracil and, regulation of thymidylate synthase, colon cancer cells (human), 527
 Interleukin 1, inhibition of formation by glucocorticoids, mediation, decreased mRNA stability (human), 176
 Interleukin 1 α , histamine-induced production, bone marrow stromal cells, inhibition by H₂ blockers (mouse), 365
 Interleukin 6
 interleukin 1 β and
 glucocorticoid formation inhibition, mRNA stability (human), 176
 triakontatetrapeptide, prostaglandins and monocytes (human), 64
 Interleukin 8, modulation by triakontatetrapeptide, role of prostaglandins, monocytes (human), 64
 Intestine
 electrolyte transport, molecular characterization, α_2 -adrenergic receptors (pig), 23
 small, cytochromes P450 probed by warfarin metabolism (rat), 226
 4-[¹²⁵I]Iodo-(2,5-dimethoxy)phenylisopropylamine, abolition of binding to 5-HT₂ receptors, single point mutation, phenylalanine, 755
 Ion currents, voltage-gated, inhalational anesthetic actions, bovine adrenal chromaffin cells, 783
 Ions, binding of cocaine analog, serotonin and dopamine transporters, 264
 Iron, acute poisoning, paraquat and desferrioxamine, electron spin resonance spin-trapping (rat), 257
 Ischemia, 22-kDa high affinity antiischemic drug-binding polypeptide, endoplasmic reticulum (guinea pig), 139
 Isoflurane, voltage-gated ion currents, bovine adrenal chromaffin cells, 783

J

- Jurkat cells, increases in cytoplasmic Ca²⁺ concentration, m3 subtype muscarinic acetylcholine receptors, 356

K

- Ketanserin
 binding to 5-HT₂ receptors, single point mutation, phenylalanine, 755
 regulation of 5-HT₂ receptors in P11 cells, agonists, partial agonists and antagonists, 726
 Kidney, cytosolic cysteine conjugate β -lyase, cDNA coding (rat), 660
 Kidney microsomes
 flavin-dependent S-benzyl-L-cysteine S-oxidase activities (rat), 388
 hydroxylation of 2- and 4-fluoroestradiol, catechol metabolites, conversion to methyl esters (hamster), 534

L

- L929 cells, *S*-adenosyl-L-homocysteine metabolism, 4'-modified analogs, aristeromycin, 989
- Ligands, binding to 5-HT_{1A} receptor, identification of residues (human), 516
- Listeria monocytogenes*, mechanism of hepatic cytochrome P450 modulation (mouse), 542
- Liver
- cytochrome P450 modulation, mechanism, *Listeria monocytogenes* infection (mouse), 542
 - inhibition and inactivation, constitutive cytochromes P450, parathion (rat), 902
 - 22-kDa high affinity antiischemic drug-binding polypeptide, endoplasmic reticulum (guinea pig), 139
 - major pathway of imipramine metabolism, cytochromes P-450 1A2 and 3A4 (human), 827
 - phenol sulfotransferase, phenol-sulfating form, complementary DNA (human), 70
 - reconstituted cytochrome P-450 oxidase system, *N*-hydroxylation of benzamidine to benzamidoimine (rabbit), 335
- Liver microsomes
- flavin-dependent *S*-benzyl-L-cysteine *S*-oxidase activities (rat), 388
 - hydroxylation of 2- and 4-fluoroestradiol, catechol metabolites, conversion to methyl esters (hamster), 534
 - purification of cytochrome P450 from monkeys, close relationship, human cytochrome P450 2B6, 183
 - transformation, *N*-hydroxynorcocaine to norcocaine nitroxide, 645
- β -Lyase, kidney cysteine conjugate, cDNA coding (rat), 660
- Lymphokines, inhibition by glucocorticoids, formation of interleukins, decreased mRNA stability (human), 176

M

- Macrophages
- cell line, cytokine-induced nitric oxide production, tetrahydrobiopterin (mouse), 6
 - peritoneal, platelet-activating factor receptor, pharmacological characterization (guinea pig), 302
- Matrigel, primary hepatocyte cultures, expression of multiple forms, cytochrome P450 mRNAs (rat), 328
- MCF-7 cells, doxorubicin-resistant, attenuation of resistance, antisense cDNA for protein kinase C α , 858
- Mesangial cells, cultured, calcium channel current (rat), 96
- [³H]-Mesulergine, abolition of binding to 5-HT₂ receptors, single point mutation, phenylalanine, 755
- N*-Methyl-D-aspartate-induced phosphatidylinositol hydrolysis, nitric oxide as mediator, neonatal cerebellum (rat), 1
- 3,4-Methylenedioxymethamphetamine, serotonin release, serotonin transporters (human), 271
- 4-Methylpyrazole, inhibition of fatty acyl coenzyme synthetase, catalase-dependent alcohol metabolism (mouse), 115
- Mianserin, regulation of 5-HT₂ receptors in P11 cells, agonists, partial agonists and antagonists, 726
- Mitomycin C
- enzyme-activated, effect of pH, DNA alkylation, 863
 - induced DNA damage, enzymatic and pH modulation, HCT 116 cells, 870
- Monoamine oxidase, A and B, site-directed mutagenesis, role of cysteines (human), 888
- Multidrug resistance, Chinese hamster ovary cells, topoisomerase II activity, cleavage of DNA, 207
- Muscimol, *t*-butylbicyclophosphoro[³⁵S]thionate and flunitrazepam, interactions with GABA_A receptors, 801
- Muscle, smooth, gastric, amino- and carboxyl-terminal domains, thrombin receptor-derived polypeptides (guinea pig), 921

Mutagenesis

- random, screening and, isolation of glucagon antagonists (rat), 741
 - site-directed
 - 5-HT₂ receptor, amino acids for ligand binding, 931
 - monoamine oxidase A and B, role of cysteines (human), 888
 - pore region, IIA sodium channel (rat), 635
- Myometrium, photoaffinity labeling, subtype 2 angiotensin receptor (human), 677

N

- Na⁺/Ca²⁺ exchanger, neuronal cells, stimulation of glutamate receptors, arachidonic acid release, 976
- Na⁺/K⁺-ATPase
- α 2 subunit isoform, adaptive supersensitivity, vas deferens (guinea pig), T1
 - inhibition of activity through protein kinase A, D_{1A} dopamine receptor stimulation, 281
- α -Naphthoflavone-induced *CYP1A1* gene expression, cytosolic aryl hydrocarbon receptor transformation (rat), 200
- Natriuretic peptide, analogs, atrial natriuretic factor-R_{1A} receptor subtype, 775
- Neonate, brain, stimulation of GABA shunt, valproate and *E*- Δ^2 -valproate (rat), 487
- Nerve growth factor, messenger RNA, regulation by β -adrenergic receptor activation, central nervous system (rat), 132
- Neural cells, SH-SY5Y, opioid tolerance, receptor mechanisms (human), 465
- Neuro-2A cells, signaling mechanism of angiotensin II, 603
- Neuroblastoma cells, differential regulation of muscarinic receptor mRNA, chronic agonist exposure, 694
- Neuronal cells, Na⁺/Ca²⁺ cells, stimulation of glutamate receptors, arachidonic acid release, 976
- Neurons
- cholinergic sensitivity, modulation by albumin (chick), 807
 - hippocampal, NMDA receptor channels, potentiation by pregnenolone sulfate (rat), 813
- Neutrophils
- crystal-induced protein tyrosine phosphorylation, tyrosine kinase inhibitor (human), 30
 - histamine-induced production of IL-1 α , inhibition by H₂ blockers, bone marrow stromal cells (mouse), 365
 - subsecond modulation, formyl peptide-linked G proteins, guanosine 5'-*O*-(3-thio)triphosphate (human), 734
- NG108-15 cells
- activation of cAMP phosphodiesterase activities, δ -opioid receptor, 684
 - compartmentation of receptors, guanine nucleotide-binding proteins, 434
 - coupling of prostaglandin E₁ receptors, stimulatory GTP-binding protein G_s, 556
 - differential regulation by ethanol, guanine nucleotide-binding protein α subunit, 158
- Nifedipine, calcium channel current, cultured mesangial cells (rat), 96
- Nitric oxide
- cytokine-induced production, tetrahydrobiopterin, macrophage cell line (mouse), 6
 - mediator of *N*-methyl-D-aspartate-induced phosphatidylinositol hydrolysis, neonatal cerebellum (rat), 1
 - signaling of angiotensin II, Neuro-2A cells, 603
- Norcocaine nitroxide, microsomal transformation of *N*-hydroxynorcocaine, reexamination, 645
- Norfloxacin-like quinolone antibacterial agents, GABA-antagonistic effects, indomethacin/ibuprofen-like anti-inflammatory agents (rat), 795
- Nucleus tractus solitarius, metabotropic glutamate receptor activation, zinc protoporphyrin-IX (rat), 965

O

- Oligonucleotides, phosphorothioate homooligodeoxynucleotides, cellular pharmacology (human), 45
- Omeprazole, nuclear uptake of Ah (dioxin) receptor, transcriptional activation, *CYP1A1* (human), 504
- Oocytes
- Xenopus*
- bicuculline/baclofen-insensitive GABA receptors, 609
- enflurane, 1,4,5-trisphosphate-mediated signaling (mouse, human), 941
- functional expression, adenosine A_{2b} receptor, 277
- Opiates, benzomorphan binding site, catalytic subunit, acetylcholinesterase, 217
- Opioids
- coupling of prostaglandin E_1 receptors, stimulatory GTP-binding protein G_{α} , NG108-15 cells, 556
- tolerance in SH-SY5Y neural cells, receptor mechanisms (human), 465
- Ouabain, adaptive supersensitivity in vas deferens, reduction in abundance, $\alpha 2$ subunit isoform of Na^+/K^+ -ATPase (guinea pig), T1
- 4-Oxoquinoline-3-carboxylic acid, quinolone antibacterial agents, inhibition, human cytochrome P450 isoform *CYP1A2*, 191

P

- P1075, binding of K^+ channel opener, aorta (rat), 474
- Pancreas, acini, regulation, phosphatidylinositol 4-kinase activity (rat), 286
- Paraquat, desferrioxamine and, electron spin resonance spin-trapping, acute iron poisoning (rat), 257
- Parathion, inhibition and inactivation, constitutive cytochromes P450, liver (rat), 902
- Patch clamp, voltage-gated ion currents, inhalational anesthetic cations, bovine adrenal chromaffin cells, 783
- P11 cells, regulation of 5-HT₂ receptors, agonists, partial agonists and antagonists, 726
- PD 85639
- inhibition of Na^+ channels, 949
- specific binding to α subunit, brain Na^+ channels (rat), 955
- PD 140376, antagonist for cholecystokinin_B/gastrin receptor, cerebral cortex and gastric mucosa (guinea pig), 595
- Pentamidine, its analogs and, DNA minor groove recognition properties, molecular modeling study, 982
- Peptides
- linear and subtype-selective, cloned somatostatin receptors, 838
- sequence-specific, development, polyclonal anti-D2 dopamine receptor antibodies, 666
- pH
- DNA alkylation, enzyme-activated mitomycin C and porfiromycin, 863
- modulation, mitomycin C-induced DNA damage, HCT 116 cells, 870
- Phenol sulfotransferase, phenol-sulfating form, complementary DNA, liver (human), 70
- Phenylalanine, single point mutation, abolition of 4-[¹²⁵I]iodo-2,5-dimethoxyphenylisopropylamine and [³H]mesulergine binding to 5-HT₂ receptors, 755
- Phosphatidylinositol
- linked acetylcholine and serotonin receptors, inhibition of function, enflurane (mouse, human), 941
- NMDA-induced hydrolysis, nitric oxide as mediator, neonatal cerebellum (rat), 1
- Phosphatidylinositol 4-kinase, regulation of activity, pancreatic acini (rat), 286
- Phosphodiesterase, cAMP, δ -opioid receptor, activation of NG108-15 cells, 684

- Phospholipase C, functional expression, adenosine A_{2b} receptor, *Xenopus* oocytes, 277
- Phosphorothioate, homooligodeoxynucleotides, cellular pharmacology (human), 45
- Photoaffinity labeling, subtype 2 angiotensin receptor, myometrium (human), 677
- Pinacidil, binding of K^+ channel opener [³H]P1075, aorta (rat), 474
- Pituitary neoplasms, multidrug resistance pump, induction of rhodamine 123 efflux, estradiol (rat), 51
- Platelet-activating factor, receptor, pharmacological characterization, peritoneal macrophages (guinea pig), 302
- Platelets
- activated, efflux of cyclic GMP (human), 564
- erythroleukemia cells, adenosine receptors (human), 909
- inhibition of signal transduction pathways, high-dose chemotherapy-induced defect (human), 37
- Polymerase chain reaction
- differential regulation, muscarinic receptor mRNA levels, neuroblastoma cells, 694
- reverse transcriptase, lack of β_3 -adrenergic receptor mRNA expression (human), 343
- Polypeptides
- 22-kDa high affinity antiischemic drug-binding, endoplasmic reticulum, liver (guinea pig), 139
- thrombin receptor-derived, amino- and carboxyl-terminal domains, vascular endothelium and gastric smooth muscle (guinea pig), 921
- Porfiromycin, enzyme-activated mitomycin C and, effect of pH, DNA alkylation, 863
- Potassium channels
- cloned, modulation of gating, micromolar Zn^{2+} (rat, human), 482
- opener [³H]P1075, binding in aorta (rat), 474
- Pregnenolone sulfate, potentiation of NMDA channels, hippocampal neurons (rat), 813
- Propafenone, *N*-dealkylation, cytochrome P450 enzymes, molecular base for interaction (human), 120
- Prostaglandin E_1 , coupling of receptors, stimulatory GTP-binding protein G_{α} , NG108-15 cells, 556
- Prostaglandin F synthase, overproduction of 37.5-kDa cytosolic protein, ethacrynic acid-resistant colon cells (human), 845
- Prostaglandins, cytokine modulation by triakontatetrapeptide, monocytes (human), 64
- Protein kinase, reversal of resistance to Adriamycin, 8-chloro-cyclic AMP, HL-60 cells, 372
- Protein kinase A, inhibition of Na^+/K^+ -ATPase activity, D_{1A} dopamine receptor stimulation, 281
- Protein kinase C
- β -adrenergic receptor- and forskolin-stimulated cAMP accumulation, inhibition by Ca^{2+} , glioma (rat), 451
- regulation of phosphatidylinositol 4-kinase activity, pancreatic acini (rat), 286
- Protein kinase $C\alpha$, antisense cDNA, attenuation of resistance, doxorubicin-resistant MCF-7 cells, 858
- Protein tyrosine, crystal-induced phosphorylation, tyrosine kinase inhibitor, neutrophils (human), 30
- Proto-oncogenes, *c-fos*, stimulation by tamoxifen, uterus (rat), 709
- Protoporphyrin-IX, zinc, metabotropic glutamate receptor activation, nucleus tractus solitarius (rat), 965
- Psychotropic drugs, tricyclic, cloning and expression, novel serotonin receptor, 320
- Purine analogues, HIV-1-specific TSAO, resistance spectrum, 109

Q

- Quinolone
- antibacterial agents
- GABA-antagonistic effects, indomethacin/ibuprofen-like anti-inflammatory agents (rat), 795
- inhibition, human cytochrome P450 isoform *CYP1A2*, 191

R

Receptors

- acetylcholine
 - inhibition of function, enflurane (mouse, human), 941
 - neuronal cholinergic sensitivity, modulation by albumin (chick), 807
- adenosine A₂, erythroleukemia cells and platelets (human), 909
- adenosine A_{2b}, functional expression, *Xenopus* oocytes, 277
- adrenergic, see Adrenoceptors
- Ah (dioxin), nuclear uptake, omeprazole (human), 504
- DL- α -amino-3-hydroxy-5-methylisoxazolepropionic acid, increase in affinity, thiocyanate (rat), 459
- angiotensin subtype 2, photoaffinity labeling, myometrium (human), 677
- atrial natriuretic factor-R_{1A}, development, natriuretic peptide analogs, 775
- benzodiazepine, ligands, recombinant GABA_A receptor subtypes (frog), 240
- bombesin, radiolabeled antagonist, subtype distinctions (guinea pig), 762
- calcitonin gene-related peptide, solubilization and characterization, guanine nucleotide-sensitive form (rat, human), 167
- cannabinoid, solubilization and interaction with G-protein, brain (rat), 17
- cholecystokinin_B/gastrin, [³H]PD 140376, cerebral cortex and gastric mucosa (guinea pig), 595
- compartmentation, guanine nucleotide-binding proteins, NG108-15 cells, 434
- cytosolic aryl hydrocarbon, transformation, α -naphthoflavone-induced *CYP1A1* gene expression (rat), 200
- dopamine D_{1A}, inhibition of Na⁺/K⁺-ATPase activity, protein kinase A, 281
- dopamine D₂, development of antibodies, sequence-specific peptides, 666
- dopamine D_{2A}D_{2B}D₃, binding characteristics, antipsychotic agents (human), 749
- GABA, bicuculline/baclofen insensitivity, *Xenopus* oocytes, 609
- GABA_A
 - α 2 and α 3 subunits, cloning of cDNA sequences (human), 970
 - muscimol, *t*-butylbicyclophosphor[³⁵S]thionate and flunitrazepam, 801
 - subtypes, benzodiazepine receptor ligands (frog), 240
- glutamate
 - arachidonic acid release, Na⁺/Ca²⁺ exchanger in neuronal cells, 976
 - zinc protoporphyrin-IX, nucleus tractus solitarius (rat), 965
- G protein-linked, labeling by [³H]histamine, cerebral cortex (guinea pig), 569, 583
- hallucinogenic, interaction of imidazolium chloride, amphetamine analogs, 78
- 5-HT
 - cloning and expression, high affinity for tricyclic psychotropic drugs, 320
 - inhibition of function, enflurane (mouse, human), 941
- 5-HT_{1A}, ligand binding, identification of residues (human), 516
- 5-HT_{1B}, masking of partial agonist activity of drugs (rat), 427
- 5-HT_{1E}-like, serotonin S31 receptor clone (human), 412
- 5-HT₂
 - agonists/partial agonists/antagonists, regulation in P11 cells, 726
 - high affinity agonist binding, sensitivity to GTP analogs (human), 915
 - messenger RNA increase, cerebellar granule cells (rat), 349
 - single point mutation, phenylalanine, 755
 - site-directed mutagenesis, amino acids for ligand binding, 931
 - up-regulation by SR 46349B, brain (mouse), 84
- 5-HT_{2F}, pharmacological characteristics (rat), 419
- 5-HT_{5A} and 5-HT_{5B}, cloning, functional expression and chromosomal localization (mouse), 313
- imidazoline, antibody-specific protein, 509
- inositol-1,4,5-trisphosphate, partial agonists, low intrinsic activity, 499
- mediated activation of GTP-binding protein/adenylate cyclase, encounter coupling model, 397
- N*-methyl-D-aspartate, potentiation by pregnenolone sulfate, hippocampal neurons (rat), 813
- muscarinic
 - compartmentation, guanine nucleotide-binding proteins in NG108-15 cells, 434
 - inhibition of GDP-activated adenylyl cyclase, carbachol (dog), 90
 - regulation of mRNA levels, neuroblastoma cells, 694
 - regulation of phosphatidylinositol 4-kinase activity, pancreatic acini (rat), 286
- muscarinic m3, increases in cytoplasmic Ca²⁺, Jurkat cells, 356
- muscarinic m4 and m5, development of antisera, brain (rat), 149
- opiate, compartmentation, guanine nucleotide-binding proteins in NG108-15 cells, 434
- opioid δ , activation of cAMP phosphodiesterase, NG108-15 cells, 684
- opioid tolerance, SH-SY5Y neural cells (human), 465
- platelet-activating factor, pharmacological characterization, peritoneal macrophages (guinea pig), 302
- polyclonal anti-D2 dopamine, antibody development, sequence-specific peptides, 666
- prostaglandin E₁, coupling to stimulatory GTP-binding protein G_s, NG108-15 hybrid cells, 556
- regulation of activity, $\beta\gamma$ subunits, guanine nucleotide-binding proteins, 245
- reserve, masking of partial agonist activity of drugs, 5-HT_{1B} receptor expression system (rat), 427
- somatostatin, subtype-selective peptides, binding of linear peptides, 838
- somatostatin 14-selective, cloning and expression, chromosome 20 (human), 894
- thrombin, polypeptides, vascular endothelium and gastric smooth muscle (guinea pig), 921
- Reserpine, adaptive supersensitivity in vas deferens, reduction in abundance, α 2 subunit isoform of Na⁺/K⁺-ATPase (guinea pig), T1
- Reverse transcriptase
 - HIV-1, kinetics, resistance to inhibitors, 521
 - HIV-1-specific TSAO, resistance spectrum, 109
- Rhodamine 123, induction of efflux by estradiol, multidrug resistance pump, pituitary tumor cells (rat), 51
- RNA, messenger
 - basic fibroblast growth factor and nerve growth factor, regulation by β -adrenergic receptor activation, central nervous system (rat), 132
 - cytochrome P450, expression of multiple forms, hepatocyte cultures maintained on Matrigel (rat), 328
 - decreased stability, inhibition by glucocorticoids, formation of interleukins (human), 176
- 5-HT₂ receptor, paradoxical increase, cerebellar granule cells (rat), 349
- inhibition of *in vitro* translation by cisplatin, prevention of formation, complete initiation complex (rabbit), 491
- lack of β_3 -adrenergic receptor expression, adipose and other metabolic tissues (human), 343
- muscarinic, differential regulation, neuroblastoma cells, 694

S

- Saxitoxin, site-directed mutagenesis, pore region, IIA sodium channel (rat), 635
- Serotonin
 - cloning and expression of novel receptor, high affinity for tricyclic psychotropic drugs, 320

release through serotonin transporters, non-neurotoxic amphetamine derivatives (human), 271
 S31 receptor clone, 5-HT_{1E}-like receptor (human), 412
 transporters, binding of cocaine analog, ionic requirements, 264
 SH-SY5Y cells, opioid tolerance, receptor mechanisms (human), 465
 Signal transduction
 inhibition of platelet pathways, high-dose chemotherapy-induced platelet defect (human), 37
 receptor mechanisms, opioid tolerance, SH-SY5Y neural cells (human), 465
 Simian virus 40, origin-dependent replication, 3'-azido-3'-deoxythymidine metabolites, HeLa cell extracts, 57
 Sodium channels
 binding of PD85,639 to α subunit, brain Na⁺ channels (rat), 955
 inhibition by PD85,639, 949
 IIA, pore region, site-directed mutagenesis (rat), 635
 immobilization of gating charge, insecticide fenvalerate, giant axons (crayfish), 626
 Somatostatin, cloned receptors, subtype-selective peptides, binding of linear peptides, 838
 Somatostatin 14-selective receptor variant, cloning and expression, chromosome 20 (human), 894
 SR 46349B, repeated administration, up-regulation of 5-HT₂ receptors, brain (mouse), 84
 Steroids, β -adrenergic receptor activation and, bFGF and NGF messenger RNA, central nervous system (rat), 132
 Stromal cells, bone marrow, histamine-induced production of IL-1 α , inhibition by H₂ blockers (mouse), 365

T

Tamoxifen, stimulation of expression, *c-fos* proto-oncogene, uterus (rat)), 709
 8784 cells, molecular cloning and expression, thiopurine methyltransferase (human), 878
 Tetrahydrobiopterin, cytokine-induced nitric oxide production, macrophage cell line (mouse), 6
 Tetrahydrocannabinol, solubilization of cannabinoid receptor, interaction, guanine nucleotide-binding proteins (rat), 17
 (5S)-4,5,6,7-Tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo [4,5,1-*jk*] benzodiazepin-2(1*H*)-thione, *see* TIBO R82150
 Tetrodotoxin, site-directed mutagenesis, pore region, IIA sodium channel (rat), 635
 Thiocyanate, affinity for two DL- α -amino-3-hydroxy-5-methylisoxazolepropionic acid receptor states (rat), 459
 Thiopurine methyltransferase, molecular cloning and expression, 8784 colon carcinoma cell cDNA (human), 878
 Thrombin, receptor-derived polypeptides, amino- and carboxyl-termi-

nal domains, vascular endothelium and gastric smooth muscle (guinea pig), 921
 Thymidylate synthase
 regulation in colon cancer cells, 5-fluorouracil and interferon- γ (human), 527
 variation, association with resistance to 5-fluoro-2'-deoxyuridine (human), 702
 TIBO R82150, resistance by single conservative amino acid substitution, reverse transcriptase, HIV-1, 11
 1,4,5-Trisphosphate-mediated signaling, enflurane, *Xenopus* oocytes (mouse, human), 941
 Tryptamines, pharmacological characteristics, 5-HT_{2F} receptor (rat), 419
 TSAO, HIV-1-specific, resistance spectrum, 109
 Tumor necrosis factor- α , modulation by triakontatetrapeptide, role of prostaglandins, monocytes (human), 64
 Tyrosine kinase, inhibitor, crystal-induced protein tyrosine phosphorylation, neutrophils (human), 30

U

UDP-glucuronosyltransferase, bilirubin, glucuronidation of ethinylestradiol (human), 649
 Uracil, DNA glycolase, mechanisms of 5-fluorouracil excision, normal cells (human), 854
 Uterus, expression of *c-fos*, stimulation by tamoxifen (rat), 709

V

Valproate, *E*- Δ^2 -valproate and, stimulation of GABA shunt, neonatal brain (rat), 487
 Vas deferens, adaptive supersensitivity, reduction in abundance, $\alpha 2$ subunit isoform of Na⁺/K⁺-ATPase (guinea pig), T1
 Verapamil, calcium channel current, cultured mesangial cells (rat), 96

W

Warfarin
 metabolism, small intestinal cytochromes P450 (rat), 226
 probe, correlation of human cytochrome P4502C substrate specificities, primary structure, 234

Z

Zinc
 micromolar, modulation of gating, cloned K⁺ channels (rat, human), 482
 modulation of drug binding, cocaine affinity states, dopamine uptake complex (rat), 100
 protoporphyrin-IX, metabotropic glutamate receptor activation, nucleus tractus solitarius (rat), 965

**Copyright © 1993 by the American Society for
Pharmacology and Experimental Therapeutics**

Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

The Journal of Pharmacology and Experimental Therapeutics

Editor: John A. Harvey, Ph.D.

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. *Monthly*

Drug Metabolism and Disposition: the biological fate of chemicals

Editor: Vincent G. Zannoni, Ph.D.

Drug Metabolism and Disposition publishes in vitro and in vivo experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants and preservatives. The areas covered are: pharmacokinetics, pharmacodynamics and mechanisms, genetic, nutritional, or hormonal factors affecting the biological fate of chemicals, toxicological consequences of xenobiotic metabolism. *Bimonthly*

Pharmacological Reviews

Editor: Robert E. Stitzel, Ph.D.

Pharmacological Reviews is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. *Quarterly*

Molecular Pharmacology

Editor: T. Kendall Harden, Ph.D.

The papers published in **Molecular Pharmacology** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. *Monthly*

Yes! Enter my subscription(s) to the following:

The Journal of Pharmacology and Experimental Therapeutics (monthly)

- ☐ Individual \$190/yr ☐ Institutional \$340/yr
(Please add \$65/yr outside the US; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Drug Metabolism and Disposition (bimonthly)

- ☐ Individual \$85/yr ☐ Institutional \$140/yr
(Please add \$20/yr outside the US; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Molecular Pharmacology (monthly)

- ☐ Individual \$105/yr ☐ Institutional \$230/yr
(Please add \$30/yr outside the US; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Pharmacological Reviews (quarterly)

- ☐ Individual \$60/yr ☐ Institutional \$107/yr ☐ In-training* \$45/yr
(Please add \$15/yr outside the US; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Payment options:

- ☐ Check enclosed (payable to Williams & Wilkins) ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

Card # _____ Exp. date _____

Signature _____

MD and PA subscribers must add appropriate state sales tax. Subscriptions outside the US must be prepaid in US dollars only. Rates valid until October 31, 1993. Please allow 10 weeks for delivery of first issue. Surface mail delivery to countries outside US may take 16 weeks. Airmail rates available upon request. *Specify institution and training status.

Name _____

Address _____

City/State/Zip _____

Return coupon to:



Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990

PT 54141

J3046S ZPTT

Mail in this coupon or call
toll-free 1-800-638-6423
(from anywhere in US or Canada)

Discounts available to members on all ASPET publications.

SAVE 10% when ordering two

SAVE 15% when ordering three

SAVE 20% when ordering all four

An important resource for everyone
involved in research on the
metabolism of drugs and chemicals

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals


Editor: **Vincent G. Zannoni, PhD**, University of Michigan,
Ann Arbor, Michigan

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. All papers are refereed to ensure a high standard of publication. The areas covered are:

- pharmacokinetics
- pharmacodynamics
- genetic, nutritional, and hormonal factors affecting the biological fate of chemicals
- toxicological consequences of xenobiotic metabolism

This journal should be a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all medicinal chemists involved in designing drugs and all biochemists involved with drug metabolism.

Bimonthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service — enter your multiyear subscription today!

Drug Metabolism and Disposition (bimonthly)

☐ Individual: \$85/yr ☐ Institutions: \$140/yr

(Please add \$20.00 outside the U.S.; in Canada, also add 7% GST.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

Payment options:

☐ Check enclosed

☐ VISA

☐ Bill me

☐ MasterCard

☐ American Express

card #

signature/P.O. #

CA, MD and PA subscribers must add state sales tax. Subscriptions from outside the US and Canada must be prepaid, *in US dollars only*. Rates valid for orders received before October 31, 1993.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

name

address

city/state/zip

Williams & Wilkins

DMD 54104

P.O. Box 23291
Baltimore, Maryland 21203-9990

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J3009S ZDMD



Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
1986 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.

Minding our P's & Q's is a high priority at Williams & Wilkins



People and Quality are the P's and Q's Williams & Wilkins represents. We put the two together because we believe the people who are important to us—our valued, longstanding subscribers—deserve the best quality products and services we can provide.

For customer service,
call TOLL FREE:
1-800-638-6423

(from anywhere in the U.S. or Canada)

Or write:
Subscription Fulfillment
Department
Williams & Wilkins
428 East Preston Street
Baltimore, MD 21202-3993

INFORMATION FOR SUBSCRIBERS

- ☐ **CHANGE OF ADDRESS.** Please notify us eight weeks in advance. Send us your mailing label or your account number, along with your new address, and the date the change of address is to take effect.
- ☐ **RENEWALS.** To ensure uninterrupted service, please renew your subscription two months prior to the expiration date of your current subscription. Current rates are available for up to three years.
- ☐ **GIFT SUBSCRIPTIONS.** Do you have a friend or colleague who shares your professional interests? Give him or her a gift subscription to your journal. For assistance with your order, contact Customer Service, using our toll-free number (1-800-638-6423).
- ☐ **CLAIMS OR CANCELLATIONS.** Claims for missing or damaged issues are honored for three months after the mailing date of the issue. If, for any reason, you are not satisfied with your subscription, you may cancel and receive a full refund on all unmailed issues.

To order back issues, bound volumes, reprints of journal articles, microfilm, microfiche, CD-ROM: Call or write Williams & Wilkins, 428 East Preston Street, Baltimore, MD 21202. Toll-free number: 1-800-638-6423.